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Therapeutic proteins and peptides are very attractive from the pharmaceutical point of view due 77 
to their high potency and selectivity. Nonetheless, their instability and low bioavailability make 78 
their administration through non parenteral routes very difficult, a fact that hampers their 79 
efficient exploitation in therapeutics. Since the 70´s, significant amount of research in the area of 80 
drug delivery and nanotechnology has been done with the final goal of overcoming those hurdles. 81 
In particular, biodegradable and biocompatible lipid and polymer-based nanocarriers have 82 
emerged as promising delivery platforms to enable the administration of proteins and peptides. 83 
This review provides an overview of the mostly explored nanotechnologies to date intended to 84 
produce lipidic and polymeric nanocarriers for protein/peptide delivery. The basic principles of the 85 
different techniques are discussed, and the main factors involved in the drug association and 86 
release, are analyzed. Finally, a brief overview of the potential applications of these 87 
protein/peptide-loaded nanocarriers, highlighting the nanomedicines that have reached the 88 
market or the clinical development phase, is provided. 89 
 90 
Keywords: protein delivery, peptide delivery, lipid formulation, polymeric formulation, 91 
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*X-ray structure of Human Recombinant insulin. Image from the RCSB PDB (www.rcsb.org) of PDB ID 5E7W. 96 
 97 
1. Introduction 98 
 99 
During the last decades, important efforts have been oriented to the commercialization of 100 
therapeutic proteins and peptides. Unfortunately, despite the well-known advantages of these 101 
drugs in terms of potency and selectivity, their exploitation is being limited by their instability, 102 
restricted bioavailability and intrinsic immunogenicity (specially for high molecular weight 103 
proteins) [1]. These draw-backs have stimulated the research in the area of drug delivery and 104 
nanotechnology with the final goal of making the administration of these powerful drugs more 105 
















The possibility of including peptides and proteins in nanovehicles that are able to protect and 108 
deliver them at the adequate site has generated increasing expectation during last decades (Fig. 1) 109 
[5]. Liposomes were the first nanocarriers proposed for protein delivery in the early 70’s [6,7]. 110 
Meanwhile, Speiser and co-workers investigated the possibility to encapsulate drugs or antigens 111 
into polyacrylic nanoparticles using micelle polymerization techniques [8]. A decade later, 112 
poly(alkylcyanoacrylate) nanocapsules were proposed as carriers for the oral administration of 113 
insulin [9]. Finally, over the 90’s Gasco et al. produced for the first time peptide-loaded solid lipid 114 
nanoparticles [10–12] and our group pioneered the development of nanoparticles made of PLGA 115 
[13], PLA-PEG [14] and chitosan [15] for the delivery of proteins and antigens. As illustrated in 116 
Figure 1, the interest around the use of all these nanocarriers for protein/peptide delivery has 117 
progressively increased in the past decades, being liposomes and polysaccharide-based 118 
nanoparticles the ones receiving the greatest attention. Noteworthy, the use of inorganic 119 
nanoparticles in the peptide/protein delivery field has grown-up during the past decade, as well. In 120 
particular, nanoparticles made of gold, iron oxide [16,17], calcium phosphate and silica likewise 121 
carbon nanotubes [18,19] have received a certain attention. However, overall, the tendency has 122 
been towards the use of biodegradable and biocompatible biomaterials that can form 123 
nanostructures based on friendly and easily scalable techniques. This tendency is expected to 124 
change the translational prospective of these delivery vehicles. Indeed, still nowadays the 125 
development of efficacious and cost–effective nano-based protein products remains a challenge 126 
and this justifies the limited number of protein/peptide-loaded nanoparticulate products in the 127 
market [20–22]. The necessity for these nanomedicines to exhibit important quality attributes 128 
such as significant drug loading, maintenance of the loaded peptide/protein activity and controlled 129 
drug release, are just some examples of the bottlenecks to be overcame [23]. 130 
 131 
Figure 1. Trend of reported experimental works concerning nanocarriers for peptide/protein delivery from the 70’s up to 132 
date. Data taken from Scopus (1971–2017) using protein/peptide delivery and the type of system as searching criteria. 133 
ME: microemulsion; NCs: nanocapsules; NE: nanoemulsion; NPs: nanoparticles; SEDDS: self-emulsified drug delivery 134 
system; SMEDDS: self-microemulsified drug delivery system; SNEDDS: self-nanoemulsified drug delivery system; SLN: 135 
















This review aims to analyze the main technologies employed until today to produce lipid and 138 
polymer-based nanoparticulate carriers for peptide/protein delivery. Additionally, a brief overview 139 
of state of the art of the protein loading, protein structural stability and release properties from 140 
these nanocarriers, as well as, their final applications, is discussed. The analysis of the technologies 141 
to produce inorganic particles and their characterization was considered to be beyond the scope 142 
of this review. 143 
 144 
2. Formulation technologies 145 
 146 
2.a. Lipid-based nanocarriers 147 
 148 
In the last decades, lipid-based nanocarriers (Fig. 2) have emerged as potential nanocarriers for 149 
macromolecular delivery. This has been mainly due to the absorption enhancing properties of the 150 
lipids and the nanocarrier’s ability to improve the drug stability. Furthermore, the biocompatible 151 
character of these biomaterials and the low cost of the production techniques have increased the 152 
interest in these nanocarriers [24]. Despite of this, the inclusion of hydrophilic macromolecules 153 
into these systems has been so far limited by their solubility. In order to improve their 154 
incorporation into these systems, many innovative strategies, which are summarized below, have 155 
been described as promising approaches for the formulation of peptide lipid-based delivery 156 
nanosystems (Fig. 3). 157 
 158 
Figure 2. Illustration of the main lipid-based nanosystems explored for protein/peptide delivery. Adapted with permission 159 
from [25].  160 
 161 
- Reverse micellization. This strategy involves the use of amphiphilic molecules able to self-162 
organize as reverse micelles exposing their hydrophobic chains to the exterior and their 163 
hydrophilic head groups to the inner part of the structure [26]. This inner cavity facilitates the 164 
incorporation of hydrophilic macromolecules prior to its inclusion in the final system [27]. 165 
 166 
- Double emulsion method. This technique consists on the formation of a W/O emulsion in which 167 
the hydrophilic drug is confined within its internal aqueous phase prior to its inclusion in the final 168 
















- Hydrophobic ion paring. This approach has been used to enhance the hydrophobicity of the 171 
drug, thereby improving its lipid solubility. It is based on the ionic complexation of a 172 
peptide/protein with a molecule, often an amphiphilic compound, with an opposite surface charge 173 
[11,31,32] or even with complex structures such as liposomes [33]. 174 
 175 
- Hydrophobic – hydrophilic interactions. This approach involves the dispersion of an aqueous 176 
solution of the hydrophilic drug into an amphiphilic compound, followed by the addition of the 177 
formed dispersion into the oily phase [34,35].  178 
 179 
 180 
Figure 3. Illustration of the main strategies employed to improve the incorporation of hydrophilic macromolecules into 181 
lipid-based delivery nanosystems. Adapted with permission from [25]. 182 
 183 
2.a.1. Liposomes 184 
 185 
Since their discovery in 1964 [36,37], liposomes have been the most extensively drug delivery 186 
vehicles investigated. To date, 13 liposome-based products have been approved for human use by 187 
the FDA [25]. Briefly, liposomes are defined as vesicles with an aqueous core in the inner cavity, 188 
surrounded by one or more bilayers of amphiphilic phospholipids. Their sizes range from 20 nm (if 189 
unilamellar) up to microns (if multilamellar) [38]. Among the wide variety of lipids, those 190 
amphiphilic able to self-assembly, such as phospholipids, phosphatidylglycerol derivatives and 191 
both saturated and unsaturated fatty acids, are the most commonly used for producing liposomes 192 
[25]. Additionally, it is also possible the inclusion of polymers and surfactants into their structure 193 
[39–42]. Finally, the use of special lipids has led to the formation of nanostructures named as 194 
archeosomes (i.e., diether or tetraether lipids) [43] and niosomes (i.e., polyoxyethylene alkyl 195 
ethers) [44], which were supposed to facilitate the entrapment of peptides and proteins [45].   196 
 197 
2.a.1.a. Preparation techniques 198 
 199 
Overall, the technologies to prepare liposomes are relatively similar. The main difference among 200 















solvents and rehydrating them in aqueous media [46]. The main liposomes preparation methods 202 
used for protein/peptide association are those described below.  203 
 204 
i) Film hydration 205 
This technique was introduced by Bangham and coworkers to produce liposomes by the first time 206 
(Fig. 4) [36,37]. This technique involves the dissolution of the phospholipids in an organic solvent, 207 
followed by the solvent evaporation and the deposition of the phospholipids forming a lipid film. 208 
Then, an aqueous solution containing the protein is added over the lipidic film to hydrate it, 209 
usually with the help of sonication, thus leading to the formation of liposomes [47,48].  210 
 211 
 212 
Figure 4. Schematic view of the film hydration technique to produce liposomes 213 
 214 
ii) Reverse-phase evaporation  215 
This technique simply involves the formation of reverse micelles by mixing an organic solution of 216 
the phospholipids with a small volume of an aqueous phase containing the peptide/protein, 217 
usually using sonication. The evaporation of the solvent results in the formation of large 218 




Figure 5. Schematic view of the reverse-phase evaporation technique to produce liposomes 223 
 224 
















- Particle size distribution: generally, a homogenization step is necessary in order to obtain a 227 
narrow particle size distribution. The homogenization of the system can be achieved using 228 
extrusion [50,51], freeze-thawing [52,53], dehydration-rehydration [54,55], sonication or high 229 
pressure. Likewise, the ratio between the different components will influence the final liposomes 230 
particle size distribution.  231 
 232 
- Peptide/protein loading and activity: liposomes have the ability to encapsulate hydrophilic (in 233 
the inner aqueous core), lipophilic (within the lipid bilayer) or amphiphilic drugs (partitioned 234 
between the lipid bilayer and the aqueous core) [56]. In general, the driving force for the 235 
encapsulation relies on the interaction between the protein/peptide and the lipids and also on the 236 
bilayer rigidity. For example, liposomes with insulin association efficiency (AE) values varying from 237 
10 up to 90 % could be obtained by changing the phosphatidylcholine:phosphatidylethanol ratio 238 
[57]. To date, a variety of peptides and proteins have been efficiently entrapped into liposomes 239 
using the preparation methods disclosed in Table 1. Unfortunately, the loading capacity of the 240 
resulting formulations has not been described or has been low (< 1 %) [58]. Therefore, the loading 241 
capacity could be considered as a limitation of these delivery carriers.  242 
 243 
Additionally, the loaded protein must remain active once encapsulated into the liposomes. The 244 
sources of peptide/protein instability differ depending on the production method considered, 245 
being the film hydration the less stressful for the integrity of the protein, even if sonication could 246 
affect its structure [59]. On the other hand,  the reverse phase evaporation technique directly 247 
exposes the peptide/protein to organic solvents, with the subsequent possibility of suffering 248 
denaturation [59,60]. Homogenization, extrusion and freeze thaw cycles can also cause protein 249 
denaturation/aggregation in both methods [59]. The integrity of the loaded peptide/protein has 250 
been studied using different methods, such as electrophoresis-based techniques (e.g. Western 251 
blot, SDS-PAGE, etc.), protein activity (particularly if the encapsulated protein is an enzyme) or 252 
directly through in vivo experiments [48,57,59,61]. 253 
 254 
- Peptide/protein release: the physicochemical properties of the phospholipids are known to 255 
determine the fluidity of the lipid bilayer and, as a consequence, influence the peptide/protein 256 
release profile. In this sense, a more sustained release is obtained when increasing the rigidity of 257 
the bilayer by the inclusion of cholesterol or long hydrophobic chains in the liposome [62]. 258 
Strategies to control the release of peptides/proteins from liposomes, such as the surface 259 
modification with polyethylene glycol (PEG) or other polymers, as well as their inclusion in other 260 
nanostructures, have been developed [58,63–66]. For example, a lower insulin release was 261 
showed after 4 hours in simulated intestinal fluids from layer-by-layer coated liposomes (20 %) 262 
compared to those uncoated (60 %) [48]. 263 
 264 
In conclusion, both film hydration and reverse phase evaporation methods are suitable for 265 
encapsulating peptides/proteins in liposomes, allowing both, good association efficiencies and 266 
sustained release profiles. The bilayer rigidity and the electrostatic interactions between the 267 















liposomes. Regarding the release behavior, not only the rigidity of the phospholipidic bilayer has 269 
an important role in controlling the release, but also factors such as PEGylation, polymer 270 
association or their inclusion in other structures can help to obtain sustained release profiles. 271 
 272 
Table 1. Examples of peptide/protein-loaded liposomes obtained by the different preparation methods: drug loading and 273 





AE (%) LC (%) 
≤1h burst/ cumulative release 





88 - 94 n.a. 
10 - 40 % / 20 - 60 % (2 h) pH 1.2  
10 - 35 % / 20 - 60 % (4 h) pH 6.8  
10 - 30 % / 72-96 % (24 h) pH 7.4 
[48] 
10 - >90 
n.a. (4 mg / 50 
mg lipid theor.) 
n.a. [57] 
sCT 91 n.a. n.a. [67] 
Leuprolide 17 - 76 n.a. n.a. / 2 - 16 % (5 h) pH 1.2* / 7.4* [68] 




Insulin 30 - 83 n.a. 
< 20 % / 50 - 95 % (30 h) pH 2* 




33 - 47 n.a. No / 40 - 50 % (2 d) pH 7.4* [69] 
66 - 72 n.a. n.a. [70] 
AE: association efficiency (100 x associated peptide mass / total peptide mass); BSA: bovine serum albumin; LC: loading 275 
capacity (100 x peptide mass / total formulation mass); n.a.: not applicable; Ref.: references; sCT: salmon calcitonin; 276 
theor.: theoretical; *Enzyme supplemented. 277 
 278 
2.a.2. Solid lipid nanoparticles (SLN) 279 
 280 
SLN are nanoparticles made of solid lipids and stabilized by surfactants. These SLN, which were 281 
first described in the 90’s [12,71], have the peculiarity of being in a solid form at both, room and 282 
body temperatures [72]. Among the wide variety of lipids, the long chain triglycerides, fatty acids 283 
and phospholipids are the most commonly used for producing SLN [25]. These lipids prevent SLN 284 
from rapid degradation, thereby facilitating the control of the drug release [72,73]. 285 
 286 
2.a.2.a. Preparation techniques 287 
 288 
A variety of techniques summarized in Table 2 have been proposed for the preparation of peptide-289 
loaded SLN.  The use of high pressure and temperature, the need of organic solvents, and/or the 290 
requirement of sophisticated equipment are the main parameters conditioning the choice of the 291 
technique to be used to prepare protein/peptide-loaded SLN. 292 
 293 
Table 2. Main characteristics of the most commonly used preparation methods for SLN 294 





















phase of a ME by dispersing 
it in cold water 




Solidification of a NE 
previously homogenized 
under heating by cooling it 
down 
High exposure to T > 









Cavitation of a pre-
suspension by homogenizing 
it at ≤RT 
Low exposure to T > 











Precipitation of the lipidic 
phase of a W/O/W emulsion 
after evaporating its solvent 
No Yes ++ 
Nanopre-
cipitation 
Precipitation of a lipid blend 
by the diffusion of the 
solvent into an aqueous 
phase 




Wide variety of methods 
based on supercritical fluid 
Depending on the 
method and the SCF 
used (usually CO2: 







HPH: high pressure homogenization; ME: microemulsion; MP: melting point; NE: nanoemulsion; pc: critical pressure; 295 
SCF: supercritical fluid; RT: room temperature; Tc: critical temperature. 296 
 297 
i) Microemulsification/solidification 298 
This method, originally developed by Gasco and coworkers [10,12] involves two different steps 299 
(Fig. 6). First, a W/O/W microemulsion containing the hydrophilic peptide in its internal aqueous 300 
phase is formed by adding an aqueous solution of the protein with the surfactant and co-301 
surfactant(s) over a melted fatty acid/glyceride mixture (65 - 70 ºC). This W/O microemulsion is 302 
then emulsified with a second aqueous phase containing surfactants. The second step consists on 303 
the dispersion of this W/O/W microemulsion in cold water (2 - 3 ºC) under mild mechanical stirring 304 
[72,74]. The addition of this thermodynamically stable microemulsion to water leads to the 305 
precipitation of its lipidic phase forming small particles [10,11]. Alternatively to the double 306 
emulsion approach, a primary O/W emulsion containing the hydrophilic peptide as hydrophobic 307 

















Figure 6. Schematic view of the W/O/W microemulsion-based technique to produce SLN 311 
 312 
ii) High pressure homogenization (HPH) 313 
High pressure homogenization is a well-established technique for the preparation of SLN, which 314 
can operate either at hot or cold temperature.  315 
 316 
- Hot Homogenization. The formation of SLN through this approach involves three different steps 317 
(Fig. 7). Generally, this method is limited to the encapsulation of hydrophobic peptides/proteins. 318 
First, a lipidic phase containing the drug either solubilized or dispersed is melted and dispersed 319 
into an aqueous surfactant-containing phase at the same temperature using a high-shear mixing 320 
device. This hot pre-emulsion consisting of micrometric droplets is then homogenized under 321 
heating until the desirable O/W nanoemulsion is formed. SLN are obtained by simply leaving the 322 
system to cool down [75]. 323 
 324 
 325 
















- Cold homogenization. The cold homogenization process emerged as an alternative to the hot 328 
procedure to minimize the drug exposure to high temperatures (Fig. 8). However, in this case it is 329 
still necessary to heat the lipids above their melting point in order to obtain a liquid phase in which 330 
the drug can be solubilized (if hydrophobic) or dispersed as an aqueous solution (if hydrophilic). 331 
Then, this melted blend is rapidly solidified, by cooling it down, using dry ice or liquid nitrogen. The 332 
obtained solid lipid matrix is then grinded in a powder mill until micrometric particles are formed. 333 
In a second step, these micrometric particles are dispersed into an emulsifier solution at or below 334 
room temperature to form a pre-suspension. Then, a final high speed homogenization process is 335 
carried out in order to break the micrometric particles into SLN [76]. 336 
 337 
 338 
Figure 8. Schematic view of the cold high pressure homogenization (HPH) technique to produce SLN 339 
 340 
iii) Double emulsion – solvent evaporation 341 
Sjöström and Bergenståhl were the first describing SLN prepared through its precipitation from 342 
O/W emulsions (Fig. 9) [77]. To our knowledge, our group was the first adapting this method for 343 
the entrapment of hydrophilic protein/peptides by the incorporation of the double emulsion 344 
approach [78]. As a first step, an aqueous solution of the protein/peptide drug is emulsified using 345 
sonication into an organic phase consisting of lipids and a water-immiscible solvent. Then, this 346 
W/O emulsion is emulsified using sonication into an external aqueous phase containing 347 
surfactants, leading to the formation of a W/O/W double emulsion. Finally, the organic solvent is 348 
removed by evaporation, thereby inducing the precipitation of the lipids in the aqueous phase in 349 

















Figure 9. Schematic view of the double emulsion – solvent evaporation technique to produce SLN 353 
 354 
iv) Nanoprecipitation 355 
This technique, illustrated in Fig.10, is based on the dispersion of a polar solvent containing the 356 
peptide/protein and the lipids in a water phase. Due to the immediate diffusion of the solvent the 357 
lipids precipitate entrapping the peptide/protein meanwhile. In principle, this technique is 358 
adapted for the encapsulation of hydrophobic peptides rather than hydrophilic proteins. However, 359 
there is also the possibility to co-dissolve a water-soluble peptide in a water/polar solvent mixture. 360 
In some instances the use of high temperature may help to co-dissolve the drug and lipids in the 361 
polar solvent [79,80]. 362 
 363 
 364 
Figure 10. Schematic view of the nanoprecipitation technique to produce SLN  365 
 366 
v) Supercritical fluid technology 367 
A new wide range of techniques based on the supercritical fluid technology have recently emerged 368 
to produce solvent-free lipid nano- and microcarriers. However, there is very limited information 369 
about protein encapsulation through these novel methods. The drug solubility in the supercritical 370 
fluid (usually CO2) is the main parameter to be considered for choosing the most appropriate 371 
procedure [81]. 372 
 373 
















The physicochemical and pharmaceutical properties of SLN might be influenced by the type of 376 
fabrication technique and the formulation variables. An overall analysis of the characteristics of 377 
SLN is as follows. 378 
 379 
- Particle size distribution: the final size of the SLN is generally influenced by the physicochemical 380 
properties (e.g. hydrophilicity, crystallization rate and crystal’s shape) and concentration of the 381 
lipids in the organic phase. A high viscosity of the lipid phase may hamper its dispersion into the 382 
water phase leading to the formation of large particles. The final size is also affected by physical 383 
factors, such as the temperature, the homogenization pressure applied during the particle 384 
formation, and the number of cycles needed to obtain the formulation. Generally, low 385 
polidispersity indexes are obtained when using high stirring rates or high number of 386 
homogenization cycles [71,72,82,83].  387 
 388 
- Peptide/protein loading and activity: in 1994,Morel et al. attempted for the first time to 389 
encapsulate peptides ([D-Trp-6] LHRH and thymopentin) into SLN [10,11] using the microemulsion 390 
based technique. Generally, the drug to be encapsulated in SLN is incorporated either directly in 391 
the lipidic phase (if hydrophobic) or using a W/O/W double emulsion approach by dissolving it in 392 
the internal aqueous phase (if hydrophilic). High AEs (79 - 98 %) and loading capacities (LCs) (6 - 13 393 
%) were attained for hydrophobic peptides such as cyclosporine A using either the microemulsion-394 
based technique [84] or the HPH methods [75]. However, for hydrophilic drugs, SLN have shown 395 
limited drug LC, being the solubility of the drug in the lipid matrix the main factor driving the AE 396 
[85]. To improve the incorporation of hydrophilic macromolecules into SLN a number of strategies 397 
highlighted in section 2.a. have been described. Among them, the double emulsion technique 398 
(W/O/W) including or not surfactants in the internal aqueous phase to form reverse micelles has 399 
been relatively successfully. This technique was first described by our group for the encapsulation 400 
of peptides into SLN, leading to the efficient association (90 %) of salmon calcitonin (sCT) [28,29]. 401 
The addition of surfactants, i.e. bile salts, into the internal aqueous phase may lead to the 402 
formation of peptide-containing micelles. This approach has led to high AE and LC values for 403 
peptides such as sCT [86]. The inclusion of the positively charged sCT and insulin in negatively 404 
charged micelles was supposedly the factor favoring the retention of the peptide in the solid core. 405 
In fact, some authors showed that the increase of the bile salt concentration and its ratio with the 406 
oily phase surfactant had a clear impact on the insulin association efficiency (AE from 20 up to 99 407 
%) [87].  408 
 409 
When using the nanoprecipitation method, variables such as the temperature of the dispersed 410 
aqueous phase was found to influence the encapsulation of hydrophilic peptides, i.e. gonadorelin 411 
(50 % AE at 25 ºC vs. 69 % at 0 ºC). This improvement can be attributed to the rapid solidification 412 
of the lipid droplets at low temperature, which would facilitate the entrapment of the peptide 413 
















As indicated, the protein/peptide stability is generally influenced by the presence of organic 416 
solvents (e.g. double emulsion/solvent evaporation or nanoprecipitation methods), high shear 417 
mechanical agitation and pressure (e.g. HPH method), high temperatures (e.g. 418 
microemulsification/solidification and HPH methods) or sonication processes (double 419 
emulsion/solvent evaporation method) [11,29,30,88]. The protein integrity and activity has been 420 
usually analyzed using the same techniques described for liposomes in the previous 2.a.1.b. 421 
section (i.e., SDS-PAGE, capillary electrophoresis, enzymatic assays and in vivo studies) [11,28–422 
30,76]. 423 
 424 
- Peptide/protein release: data indicated in Table 3 highlight the high variability in the release 425 
profiles observed for different peptides/proteins entrapped in a variety of SLN [28,78,79]. 426 
Although in some works, no burst release was reported, normally there is a variable amount of 427 
peptide accumulated at the O/W interface during the production process that is released 428 
prematurely [72]. This burst effect and the subsequent release profile has been modulated 429 
following specific formulation approaches. In particular, the overall release profile is highly 430 
dependent on the SLN composition, since it is mainly governed by the peptide diffusion through 431 
the channels, originally present in the matrix, and enlarged in the course of the lipase-mediated 432 
lipids degradation [78]. These findings suggest that a selection of the lipidic components is 433 
important in order to modulate the protein/peptide release. 434 
 435 
It is important to highlight the possibility of an interaction between the peptide/protein and the 436 
lipid components and their degradation products. For example, in a work intended to encapsulate 437 
leuprolide acetate into SLN using the nanoprecipitation technique, the use of a  hydrophobic ion 438 
pairing complex between leuprolide and sodium stearate led to a considerable reduction of the 439 
burst effect (1 h burst release: 10 % vs. 45 %). Following this initial fast release, the peptide was 440 
slowly released for up to 2 days [80]. In another example the sustained release of sCT (40 - 45 % in 441 
6 h) from chitosan-coated SLN produced by the double emulsion-solvent evaporation method was 442 
attributed to the high affinity of the positively charged sCT for the negatively charged lipids 443 
(lecithin and tripalmitin) [28]. 444 
 445 
The incorporation of PEG into the lipid matrix has also been proposed as a strategy to modulate 446 
the release profile. For example, the release of insulin from SLNs produced by the supercritical 447 
fluid technology, could be controlled by incorporating 5 kDa PEG in the lipid mixture as a pore-448 
forming agent [89]. Indeed, the total amount of insulin associated to PEG-containing SLNs was 449 
released in 3 days, whereas PEG-free SLNs needed 5 days to deliver their content.  450 
 451 
From the results in literature up to date (Table 3 shows some examples), we can conclude that the 452 
release of peptides from SLN is affected by the composition of the lipidic matrix (governing the 453 
degradation of the particles) and by the affinity of the peptide/protein towards the formulation 454 
components. Normally, the in vitro release of the proteins/peptides is prolonged for a few days, 455 
however, it could be expected that in an in vivo situation the process could be accelerated 456 
















Table 3. Examples of peptide/protein-loaded SLN obtained through the different preparation methods: drug loading and 459 







AE (%) LC (%) 
≤1h burst / cumulative 












90 n.a. <3 % / 10 % (8 h) pH 6.5 [10] 
Thymo-
pentin 






5 n.a. <5 % / 10 % (6 h) pH 6.5 
Hot HPH - CyA 
95 - 98 
0.5 - 2 
theor. 
n.a. [75] 
96 1.9 n.a. [90] 
Cold HPH - 
CyA 79 - 94 
0.5 - 2 
theor. 
n.a. [75] 













sCT 88 - 95 5 - 11 
60 - 100 % / 100 % (2 h) 
pH 6.8* 
[86] 
Insulin 76-100 19 








50 - 69 n.a. 





















20 - 80 1 - 4 




<10 % / 100 % (4 d)  
pH 7.4 [91] 
rh-GH 48 2.4 <5 % / 100 % (4 d) pH 7.4 
AE: association efficiency (100 x associated peptide mass / total peptide mass); CyA: cyclosporine A; [D-Trp-6] LHRH: 461 
agonist triptorelin - luteinizing hormone-releasing hormone; HPH: high pressure homogenization; LC: loading capacity 462 
(100 x peptide mass / total formulation mass); n.a.: not applicable; Ref.: references; rh-GH: recombinant human growth 463 
hormone; sCT: salmon calcitonin; theor.: theoretical; *Enzyme supplemented. 464 
 465 
2.a.3. Microemulsions and Nanoemulsions 466 
 467 
Both, water-in-oil (W/O) and oil-in-water (O/W) microemulsions are usually considered as 468 















microemulsion formation has been described as a spontaneous process that occurs after mixing 470 
the oil and the water phases containing a certain amount of surfactants, in order to achieve a low 471 
interfacial tension between the two phases [92]. Nanoemulsions have also been described as 472 
colloidal dispersions that generally display sizes below 200 nm. In contrast with microemulsions, 473 
these systems are not isotropic. The nanoemulsion formation requires an external energy input in 474 
order to overcome their positive free energy and increase their contact area, leading to the 475 
formation of a kinetically stable colloidal dispersion [93]. A special type of emulsions is the one 476 
present in the self-emulsifying drug delivery systems (SEDDS) and the self-micro-emulsifying drug 477 
delivery systems (SMEDDS) which typically consist of mixtures of oil, surfactant and co-surfactants. 478 
Recently, many of these SMEDDS have been classified as self-nanoemulsifying systems (SNEDDS) 479 
[94]. Among the wide variety of lipids, the long and medium chain glycerides and fatty acids are 480 
the most commonly used for the preparation of self-emulsifying systems, microemulsions and 481 
nanoemulsions containing peptides [25]. Medium chain fatty acids are known to improve the 482 
peptide solubility and facilitate the emulsification process since their mixture with the aqueous 483 
phase is easier.  484 
 485 
2.a.3.a. Preparation techniques 486 
 487 
A wide variety of methods have been developed to produce micro/nanoemulsions. These 488 
techniques can be classified depending on the procedure used to supply energy to the system [95–489 
97], being broadly categorized into the following two groups: i) High-energy processes, which 490 
imply the application of mechanical and intensive disruptive forces to the different phases of the 491 
system. Special devices are necessary in order to intermingle the oily and the aqueous phases, 492 
leading to the formation of nanodroplets (homogenization, microfluidization and ultrasonication) 493 
[98–100]; ii) Low-energy processes (spontaneous emulsification and phase inversion), which are 494 
based on the spontaneous formation of nanoemulsions either by changing the composition (i.e., 495 
ratio surfactant:oil:water, addition of salts, etc.) or the process conditions (i.e., temperature-time 496 
profile, stirring, addition speed, etc.) [97,101–104]. Among the wide variety of techniques, those 497 
based on the spontaneous emulsification are, so far, the most commonly used for the association 498 
of peptides/proteins. This is mainly due to the fact that this method avoids the peptides/proteins 499 
being exposed to any temperature or pressure stress. 500 
 501 
i) Spontaneous Emulsification. 502 
Through this method, the nanoemulsion is spontaneously formed upon the mixture of the oily and 503 
the aqueous phases (Fig. 11) [105,106]. The protein/peptide is included in one of them depending 504 
on its hydrophilicity or incorporated into the oily phase in a small amount of water. Both phases 505 
are immiscible in each other; however, one of the components present in one of them (i.e., an 506 
organic solvent, a surfactant) is partially miscible in both. Once the two phases are in contact, a 507 
non-equilibrium state is formed, causing the rapid shifting of the miscible component from its 508 
original phase into the other. This fact will lead to an increase in the oil-water interfacial area and 509 

















Figure 11. Schematic view of the spontaneous emulsification technique to produce nanoemulsions 513 
 514 
2.a.3.b. Characterization, peptide/protein loading, activity and release profile 515 
 516 
- Particle size distribution: by selecting appropriately the ingredients and the preparation method, 517 
emulsions showing a wide range of sizes, charges and physical properties can be obtained. The 518 
final size distribution of the emulsion can be modulated by optimizing its composition 519 
(concentration of the components, ratio surfactant:oil:water, interfacial tension, viscosity, 520 
emulsifier adsorption kinetics, etc.) and the operating conditions (temperature-time profile, 521 
stirring rate, pressure, amplitude of sonication and number of cycles, etc.) [108–111]. The use of 522 
ternary phase diagrams is an useful tool to predict the optimum conditions for the formation of 523 
the nanoemulsion [112,113]. 524 
 525 
- Peptide/protein loading and activity: the combination of the spontaneous emulsification 526 
technique with several specific strategies, such as, double emulsification, reverse micellization, 527 
hydrophobic ion paring or peptide-lipid/surfactant interaction (section 2.a.) has been effective for 528 
the loading of hydrophilic peptides (Table 4) such as insulin, with AEs higher than 85 % 529 
[27,35,114,115]. Among the factors influencing this association, it has been found that small 530 
variations in the final pH (from 6.5 to 6.8), may lead to sharp decreases in the AEs from 79 to 30 %. 531 
This result was attributed to the different ionization degree of both, the peptide and the polymer 532 
at the selected pHs, and their electrostatic and/or hydrophobic interactions [116]. Despite the 533 
good association efficiencies achieved, the loading capacity of these systems is usually lower than 534 
1 % [31,117]. 535 
 536 
After system preparation, the loaded peptide/protein must be able to keep its activity. In fact, 537 
there are some operation conditions, i.e. the use of organic solvents and surfactants, which can 538 
lead to protein denaturation and/or aggregation. High shear agitations, temperatures or pressures 539 
can affect the integrity of the protein, as well [31,118,119]. In this regard, the use of ELISA assays 540 
has been reported as an efficient method to understand if the activity of the encapsulated protein 541 
is kept. However, in the specific case of micro- and nanoemulsions, direct in vivo evaluation of the 542 
formulation is the main approach reported to evaluate the efficacy of the loaded therapeutic 543 
agent [118,120]. 544 
 545 
- Peptide/protein release: only a few papers have been published dealing with the mechanism 546 















release of the drug has been related to its partition between the emulsion and the surrounding 548 
medium and also to the alteration/degradation of the lipidic components. For example, when they 549 
are orally administrated, their contact with the gastrointestinal fluids can cause a phase inversion 550 
or separation of the emulsion phases, that may lead to a premature drug release [120,121]. The 551 
conversion of these liquid systems into solid forms through freeze drying, spray drying, melt 552 
granulation, melt extrusion or adsorption over solid carriers has been proposed as a way to 553 
overcome the colloidal instability of these systems [122]. Further improvements of this technology 554 
in order to optimize the delivery of hydrophilic drugs from self-emulsifying systems are still 555 
needed. However, for lipophilic peptides, some formulations, such as Neoral® (SMEDDS containing 556 
cyclosporine) have already been marketed [1]. 557 
 558 
Table 4. Examples of peptide/protein-loaded micro/nanoemulsions and SEDDS/SMEDDS/SNEDDS obtained through the 559 
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90 % / 100 % (2 h)  
pH 6.4/1.2* 















<20 % / 40 % of complex 




















AE: association efficiency (100 x associated peptide mass / total peptide mass); LC: loading capacity (100 x peptide mass 561 
/ total formulation mass); n.a.: not applicable; Ref.: references; rhPTH1-34: recombinant 1-34 N-terminal fragment of 562 
endogenous human parathyroid hormone; sCT: salmon calcitonin; TAMRA: tetramethylrhodamine; TAT: HIV 563 
transactivator of transcription; theor.: theoretical; *Enzyme supplemented. 564 
 565 
2.a.4. Nanocapsules  566 
 567 
Nanocapsules are core-shell structured drug delivery carriers. They consist of an oily core which is 568 
stabilized by surfactants and it is surrounded by one or more polymer shells [127]. Both, core and 569 
outer shell layers, play a crucial role in the outcome of the formulation: whereas the core usually 570 
works as a drug reservoir, the polymer coating helps the associated drug to overcome biological 571 
barriers and modulate its release profile. Among the wide variety of lipids, the long chain fatty 572 
acids and the medium chain glycerides (mono-, di- and tri-), both showing penetration enhancer 573 
properties, are the most commonly used for producing nanocapsules [25]. 574 
 575 
2.a.4.a. Preparation techniques 576 
 577 
The preparation of nanocapsules involves the emulsification of an oily phase into an aqueous 578 
phase. The polymer forming the shell can be incorporated into the organic phase or the aqueous 579 
phase [128,129]. Additionally, two different polymers can be incorporated one in each phase 580 
[130,131]. The shell is formed due to its precipitation at the interphase or to an ionic interaction 581 
between the oily core and the polymer. In a different situation, i.e. poly(alkylcyanoacrylates), the 582 
polymer shell is formed due to an interfacial polymerization process [9,132]. The main factors 583 
driving the choice of the appropriate nanocapsules production technique are the nature of the 584 
polymer as well as that of the peptide/protein to be encapsulated (Table 5). 585 
 586 
Table 5. Main characteristics of the most commonly used preparation methods for nanocapsules 587 
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In this method, which is also named as interfacial polymerization, the polymer formation occurs 590 
“in situ” at the interface of an emulsion through a fast polymerization among reactive monomers. 591 
Due to their rapid and easy polymerization, alkylcyanoacrylates have been the monomers of 592 
choice for this purpose [133,134]. Unfortunately, the potential reaction between the drug and the 593 
reactive monomers during the process constitutes a limitation of this approach [135]. 594 
 595 
- Interfacial polymerization in oily core nanocapsules. In this case, the organic phase is composed 596 
by the peptide/protein, the oil, the monomers and an organic solvent. The solvent needs to be 597 
water-miscible in order to promote its diffusion towards the aqueous phase, allowing the 598 
spontaneous formation of nanometric oily droplets [136]. The organic phase is usually injected 599 
into the aqueous phase, which contains at least a hydrophilic surfactant. This process is usually 600 
performed under vigorous stirring, leading to the instantaneous formation of the nanocapsules 601 
(Fig. 12). An additional final step to remove the organic solvents can be performed [9,134]. 602 
 603 
 604 
Figure 12. Schematic view of the interfacial polymerization technique to produce oily core nanocapsules  605 
 606 
- Interfacial polymerization in aqueous core nanocapsules. In this method, the aqueous phase, 607 
which contains the protein/peptide, water and sometimes water-miscible solvent, is emulsified 608 
into an organic phase consisting of an oil and a lipophilic surfactant using sonication or vigorous 609 
stirring. Once the W/O emulsion is formed, the monomers are added under mechanical stirring. 610 
This last step, triggers the polymerization at the W/O interface and leads to a final system 611 
consisting of aqueous core nanocapsules dispersed in oil (Fig. 13) [137,138]. The nanocapsules are 612 

















Figure 13. Schematic view of the interfacial polymerization technique to produce aqueous core nanocapsules 616 
 617 
ii) Polymer precipitation/deposition 618 
Contrarily to the “in situ” polymerization, the use of preformed polymers allows a good control of 619 
the final polymer molecular weight, avoiding undesirable reactions between the drug and 620 
monomers. In this case, the polymer coating can be formed by either polymer precipitation or 621 
polymer deposition/interaction.  622 
 623 
- Polymer precipitation. This technology was first reported by Fessi and coworkers [141,142]. This 624 
method involves the use of an organic polar phase containing a lipophilic surfactant, an oil, and 625 
the polymer, and an aqueous phase, that may contain hydrophilic surfactants. The usual 626 
procedure can be summarized as follows (Fig. 14): the organic phase is added dropwise over the 627 
aqueous phase under moderate stirring leading to the instantaneous diffusion of the water-628 
miscible solvent from the lipophilic solution to the aqueous phase. As a consequence, the polymer 629 
precipitates at the interface of the formed oily droplets, stabilizing them. In a final step, solvents 630 
can be removed by evaporation under vacuum [128,130,142]. 631 
 632 
- Polymer deposition/interaction. Alternatively, nanocapsules can be produced using water 633 
soluble polymers according to a deposition/interaction technique. In this case, the polymer shell is 634 
formed due to its ionic interaction with the lipophilic components of the oily core. This interaction 635 
may occur during the solvent displacement process or after the incubation of the preformed 636 
nanoemulsion with the water-soluble polymer [123,129,143,144]. Additionally, the possibility of 637 
obtaining multi-layer nanocapsules has been reported. This layer by layer approach is based on the 638 
adsorption of different polymeric layers onto a colloidal template. The addition of each polymeric 639 
layer should invert the overall charge of the system in all the absorption steps [127]. Our group 640 
has reported the possibility of obtaining protein-loaded nanocapsules by triggering the polymer 641 
deposition by a self-emulsification method avoiding the use of organic solvents. The principle of 642 















micro/nanoemulsions (Fig. 11), including, additionally, a water-soluble polymer into the aqueous 644 
phase [145] or in a subsequent incubation step [146,147]. 645 
 646 
 647 
Figure 14. Schematic view of the solvent displacement - polymer precipitation/deposition technique to produce 648 
nanocapsules 649 
 650 
2.a.4.b. Characterization, peptide/protein loading, activity and release profile 651 
 652 
- Particle size distribution: the main factors affecting the final particle size distribution of 653 
nanocapsules are the ratio and the mixing conditions between the two phases, as well as the 654 
physicochemical properties and concentration of the different components 655 
[119,128,129,148,149]. Overall, nanocapsules have been produced so far with a size between 30 656 
and 400 nm.  657 
 658 
- Peptide/protein loading and activity: Couvreur and coworkers were the first reporting the 659 
possibility of using nanocapsules as delivery vehicles for proteins [9]. Since their contribution 660 
through the encapsulation of insulin in poly(alkylcyanoacrylate) nanocapsules, several authors 661 
have demonstrated the capability of nanocapsules to entrap different peptides/proteins (Table 6). 662 
Despite the high AEs attained, the LC values reported so far are below 2 %, which is usually due to 663 
the hard solubilization of hydrophilic peptides into the lipidic phase and their tendency to diffuse 664 
to the outer aqueous phase [139]. When nanocapsules are obtained by interfacial polymerization, 665 
the monomer concentration has been proved to be one of the main factors influencing the 666 
peptide association efficiency [150]. The pH of the peptide solution has also been shown to 667 
influence the AE of peptides to PACA nanocapsules. This effect is attributed to the influence of the 668 
pH on the polymerization rate of the polymer [148]. 669 
 670 
Our group has also shown the possibility to attach proteins to preformed polymer nanocapsules. 671 
For example, we have efficiently associated the recombinant hepatitis B surface antigen (rHBsAg) 672 
onto preformed chitosan nanocapsules. In this situation the attachment of the protein was found 673 
to be dependent on both protein and nanocapsules concentration and the mechanism of 674 
attachment was based on ionic/hydrophobic interactions [151–153]. 675 
 676 
Different formulation parameters could influence the peptide/protein structure. With “in situ” 677 















denatured and losing its activity. However, ethanol can be used to preserve the peptide/protein 679 
structure [154]. Furthermore, in all the techniques described above for nanocapsules production, 680 
the presence of organic solvents and surfactants, as well as the vigorous stirring, could also affect 681 
the structure of the encapsulated peptide/protein [139,143,148]. Electrophoresis-based 682 
techniques (e.g. native SDS-PAGE), HPLC-based methods or circular dichroism have been reported 683 
to study the structural stability of nanoencapsulated peptides/proteins [139,148,154]. However, in 684 
the majority of the works, the activity of the encapsulated drug was evaluated after its in vivo 685 
administration [128,143,155]. 686 
 687 
- Peptide/protein release: the mechanism driving the release of peptides/proteins entrapped into 688 
nanocapsules has been defined as a combination of two main processes: the partition of the drug 689 
between the nanocarrier and the external release medium and the degradation of the polymer 690 
shell and the lipid core. Both processes can be affected  by different factors, such as the pH of the 691 
release medium, the nature of the lipidic cores, the type and molecular weight of the polymer, as 692 
well as the thickness of the polymer shell [138,143,149,156]. BSA cumulative releases ranging 693 
from 35 % up to 90 % were reported for poly(butylcyanoacrylate) nanocapsules after 8 h in release 694 
media with different pHs (from 2.5 to 8.5) and different profiles were showed when 695 
poly(butylcyanoacrylate) of 4, 7 or 10 kDa was used. Likewise, the loading and the molecular 696 
weight confer the protein with different diffusion capacities and specific interactions with the 697 
components of the system. High loadings increase the protein gradient between the nanocapsule 698 
core and the outer phase, and proteins with high molecular weights diffuse more slowly through 699 
the polymeric wall [139]. On the other hand, when the protein is attached to the polymer shell, 700 
the mechanism of release is based on its disassociation [157] and this process is normally 701 
dependent on the pH and ionic strength of the release medium.  702 
 703 
From the results in literature up to date, we can conclude that the solvent displacement technique 704 
is the most advantageous for encapsulating hydrophilic peptides in nanocapsules. Apart from its 705 
simplicity, and the possibility of controlling the exact molecular weight of the polymer and 706 
avoiding undesirable cross-reactions, high association efficiencies can be attained.  707 
 708 
Table 6. Examples of peptide/protein-loaded nanocapsules obtained by the different preparation methods: drug loading 709 
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10 % / 13 % (5 h) pH 7.4/1-2*  




57 - 95 n.a. n.a. 
[148, 
162] 
100 n.a. n.a. [163] 



















60 n.a. n.a. [132] 
Insulin 
63 - 97 n.a. 
25 - 50 % / 50 - 70 % (6 h) pH6.8  
No / <5 % (2 h) pH 1.2 
[137, 
138] 
12 - 52 0.6 - 1.8 35 - 90 % / 80-100 % (6h) pH 6.8 
[156, 
165] 
OVA 8 - 95 n.a. n.a. [150] 
BSA 
90 n.a. n.a. [166] 
n.a. 1 - 4 
15 - 60 % / 60 - 90% (9 h) pH 7.4 





95 - 99 n.a. 
No / <11 % (5 d) pH 7.4 
No / <5 % (6 h) pH 6.8*/1.2* 










51 - 62 0.8 - 1 
20 - 30 % / 20 - 40 % (6 h) 
pH 1.2/6.8/7.1 













n.a. / 10 % (4 h) pH 6.8 [155] 
Pliti-
depsin 
98 - 99 0.54 60 - 70 % / 60-70% (24 h) pH 7.4 [124] 




rHBsAg 55 - 83 n.a n.a 
[151–
153] 
CyA 95 5 n.a. [146] 
AE: association efficiency (100 x associated peptide mass / total peptide mass); BSA: bovine serum albumin; CyA: 711 
cyclosporine A; D-Lys6-GnRH: agonist gonadotropin releasing hormone; LC: loading capacity (100 x peptide mass / total 712 
formulation mass; n.a.: not applicable; OVA: ovalbumin; Ref.: references; rHBsAg: recombinant hepatitis B surface 713 
antigen; sCT: salmon calcitonin; theor.: theoretical; *Enzyme supplemented. 714 
 715 
2.b. Polymer-based nanocarriers 716 
 717 
Polymer-based nanocarriers (Fig. 15) have been widely used for the delivery of proteins and 718 
peptides. Both, hydrophobic (e.g. poly(lactide-co-glycolide) and hydrophilic (e.g. polysaccharides) 719 















with some promising results. Here, a brief overview of the polymers and techniques used to 721 
produce protein/peptide-loaded nanoparticles is given. 722 
 723 
 724 
Figure 15. Illustration of the main polymer-based nanoparticles (NPs) used for protein/peptide delivery. 725 
 726 
2.b.1. Polyesters-based nanocarriers 727 
 728 
Polyesters such as poly(lactide-co-glycolyde) (PLGA), poly(lactide) (PLA) and poly(ε-caprolactone) 729 
(PCL), are the most commonly used polymers for pharmaceutical applications, with PLGA as 730 
principal polymer for nanoparticles production [169]. In addition, following our discovery on the 731 
positive role of the PLGA PEGylation in protein formulation, a number of studies have adopted this 732 
strategy [170,171]. 733 
 734 
PLGA is a synthetic co-polymer composed of a mixture of two structural monomer units: lactic acid 735 
and glycolic acid (the monomers which form respectively PLA and PGA). For the purpose of 736 
peptide/protein delivery using PLGA nanoparticles, the cargo can be localized either inside the 737 
polymer matrix or attached on its surface (adsorbed or covalently linked) [172,173]. The main 738 
interest of these polymers relies on the fact that they are part of a number of marketed 739 
formulations, some of them containing peptides [174]. 740 
 741 
2.b.1.a. Preparation techniques 742 
 743 
In general the principles for the formation of these nanoparticles involve the dissolution of the 744 
protein in an aqueous phase and the dissolution of the polymer in an organic solvent. The main 745 
difference among techniques resides in the nature of the organic solvent in which the polymer is 746 
dissolved, and in the composition of the external aqueous phase. In the case that the polymer is 747 
dissolved in a non-polar solvent, i.e. ethyl acetate, the protein solution forms an emulsion and this 748 
emulsion could be subsequently emulsified in a water phase (double emulsion-solvent 749 
evaporation) or precipitated in a polar solvent external phase (emulsion-solvent diffusion). When 750 
the polymer is dissolved in a polar solvent the protein is co-dissolved in this phase, and this polar 751 
phase can be precipitated upon solvent diffusion in water (nanoprecipitation).On the other hand, 752 















achieved using minor energy sources (regular agitation) in the case of emulsion-solvent diffusion 754 
and nanoprecipitation or high energy sources in the case of double emulsion-solvent evaporation.  755 
 756 
Finally, it is important to highlight that the microfluidics approach is currently receiving a great 757 
attention as a way to mix the phases. In fact, microfluidic devices can control the way the different 758 
phases are mixed with each other, with the possibility of tuning the physicochemical properties of 759 
the particles formed [175–177]. 760 
 761 
Table 7 gives an overview of the techniques employed to produce polyester-based nanoparticles 762 
for protein/peptide delivery. 763 
 764 
Table 7. Main characteristics of the most commonly used techniques to form peptide/protein-loaded polyester-based 765 
nanoparticles 766 




Double emulsion - 
solvent evaporation 
Double emulsion and 
precipitation of the 
polymer due to 








precipitation of the 
polymer due to the 
diffusion of the solvent 




Yes  + 
Nanoprecipitation 
Polymer precipitation into 
a non-solvent external 
phase 
No Yes  + 
 767 
i) Double emulsion-solvent evaporation 768 
This technique was described in the early 90’s for the microencapsulation of proteins, and, a few 769 
years later, our group pioneered its adaptation to the encapsulation of proteins within 770 
nanoparticles of around 200 nm [178]. The principle involves the emulsification of an aqueous 771 
solution containing the protein/peptide into an organic non-polar solvent (i.e. methylene chloride 772 
or ethyl acetate) containing the polymer (i.e. PLGA), thereby forming a W/O emulsion. This W/O 773 
emulsion is then emulsified again in a volume of an external aqueous phase containing a 774 
surfactant (i.e. polyvinylalcohol (PVA)). The solvent present in the resulting double emulsion is 775 
eliminated by evaporation [173,178,179]. The two emulsification processes require the use of high 776 
energy sources (homogenization, sonication or high speed vortex in the case of small volumes). A 777 

















Figure 16. Schematic view of the double emulsion-solvent evaporation procedure to produce polyester-based 781 
nanoparticles 782 
 783 
ii) Emulsion -solvent diffusion 784 
As in the previous method, an aqueous solution of the peptide/protein is emulsified in an organic 785 
non-polar phase containing the polymer and potentially some surfactants. Then, this emulsion is 786 
added to an external polar phase (a mixture of water and ethanol) in which the organic solvent is 787 
miscible. As a consequence, the polymer precipitates into the polar phase (polymer non-solvents), 788 
causing the formation of the nanoparticles (Fig.17) [180–183]. A final evaporation step is 789 
necessary to remove the organic solvents. 790 
 791 
 792 
















iii) Nanoprecipitation 795 
According to this method, the polymer and the proteins are dissolved into a water-miscible 796 
organic solvent that is then added dropwise or injected into a dispersing phase in which the 797 
polymer is not soluble (Fig. 18). The rapid shifting of the solvent into the water causes the 798 
nucleation of the polymer, which aggregates, forming the nanoparticles [184,185]. A final 799 
evaporation step to remove solvent traces is usually done. 800 
 801 
 802 
Figure 18. Schematic view of the nanoprecipitation method to produce polyester-based nanoparticles 803 
 804 
2.b.1.b. Characterization, peptide/protein loading, activity and release profile 805 
 806 
- Particle size distribution: the nanoparticles production technique and the associated formulation 807 
parameters have been reported to influence the final particle size distribution. For example, in the 808 
case of the double emulsion-solvent evaporation, the size of the particles is highly dependent on 809 
the type of instrument and energy applied during the mixing of the organic and aqueous phases. 810 
Additionally, the polymer concentration and the type and amount of surfactants added to the 811 
formulation may affect the particle size distribution [186,187]. In the case of the solvent-812 
diffusion/nanoprecipitation based techniques, the particle size is mainly determined by the 813 
polymer concentration and the rate of mixing the two phases. In general, for protein delivery 814 
purposes, particles sizes between 100 and 300 nm and negative surface charges are reported 815 
[181,183,185,188]. 816 
 817 
- Peptide/protein loading and activity: most of the articles reporting the encapsulation of 818 
peptides/proteins within PLGA nanoparticles, refer to high AE values, however the final LC is not 819 
normally reported and it is usually lower than 5 % [181,182,188]. Both, the AE and LC depend on 820 
the preparation technique and also on a number of formulation factors, which include the type of 821 
PLGA (ratio lactic/glycolic acid), its molecular weight, its concentration in the polymer solution, the 822 
presence of stabilizers or other formulation additives, as well as the type and theoretical loading 823 
of the protein. For example, the molecular weight of the polymer and its hydrophobicity have 824 
influenced the L-asparaginase loading capacity of PLGA nanoparticles, showing values ranged from 825 
1.8 up to 4.9 % LC [189].The highest LC was achieved with high molecular weight-hydrophilic 826 
polymers, which was rationalized as follows. While the presence of free carboxylic groups in the 827 
chains of the hydrophilic polymers facilitated its interaction with the protein, the high molecular 828 















from the organic phase to the external aqueous medium. In a different study it was found that the 830 
presence of mannosamine covalently attached to PLGA nanoparticles produced by double 831 
emulsion/solvent evaporation led to an increase in the association of insulin compared to the 832 
unmodified PLGA particles (68 vs 77 % AE; 3.5 vs 4 % LC), probably due to an interaction between 833 
the mannosamine residues and the protein [190]. On the other hand, the pH of the internal 834 
protein-containing aqueous phase has also been shown to influence the association of BSA to 835 
PLGA nanoparticles. Indeed, in a particular study, it was shown that a pH value near the BSA 836 
isoelectric point led to a significant increase in the BSA association due to an increase in its 837 
hydrophobicity [188]. 838 
 839 
Finally, it is important to highlight that the presence of stabilizers such as sodium bicarbonate, 840 
trehalose or poloxamer 188 in the inner aqueous phase were found to help the stability of the 841 
protein during the nanoparticles preparation procedure, although this was normally associated to 842 
a decrease in AE values [178,191]. In another case, it was shown that the presence of both, 843 
heparin and BSA, as formulation additives was fundamental to increase the association of PDGF-844 
BB (platelet-derived growth factor) (from 35 % to 87 %) into PLGA nanoparticles produced by the 845 
solvent diffusion technique. This was attributed to the surfactant properties of BSA, which led to a  846 
reduction of the contact of the growth factor with the water/oil interface, thus increasing the 847 
association of the protein to the nanoparticles [182].  848 
 849 
In fact, the main source of peptide/protein instability common to all the above described 850 
techniques is the presence of organic solvents, which can cause denaturation and/or aggregation. 851 
The use of stabilizing additives (e.g. methyl-β-cyclodextrins, BSA or PEG) could increase the 852 
stability of the drugs, helping them to keep their structure [182,184,185]. Sonication (for double 853 
emulsion-solvent evaporation) and the presence of surfactants (for both double emulsion-solvent 854 
evaporation and emulsion-solvent diffusion) can also affect the peptide protein/structure [184]. 855 
HPLC, ELISA and enzymatic assays have been used to evaluate both encapsulation and structural 856 
stability of peptides/proteins [182,184,191]. Direct in vivo evaluation of the formulation has also 857 
been reported with the same aim [191]. 858 
 859 
- Peptide/protein release: the typical protein release profile from PLGA nanoparticles consists of 860 
an initial burst followed by a sustained release that may last from days to weeks depending on the 861 
characteristics of the PLGA nanoparticles. In general, the first fraction of protein released is the 862 
one located close to the surface of the particles [181]. Then, the release of the entrapped protein 863 
is triggered by the degradation of the polymer by erosion, followed by the diffusion of the protein 864 
through the channels created in the process [192]. This erosion process is known to generate 865 
oligomers that can easily interact with the encapsulated protein leading to its denaturation [193]. 866 
Based on this finding, we have developed a variety of strategies to prevent this critical problem. 867 
These include the incorporation of surface active materials, i.e. block copolymers of poly(ethylene 868 
oxide) (PEO) and poly(propylene oxide) (PPO) [178,181], as well as the use of PEGylated PLGA 869 
[170,171]. In both situations, the presence of PEG molecules inside the PLGA matrix was found to 870 















mechanism of release is mainly driven by the degradation of the polymer, the nature of the 872 
protein may also influence its solubility, its interaction with the polymer and its diffusion across 873 
the channels generated in the polymer degradation process [171,183,188,190,194].  874 
 875 
Table 8 shows examples of proteins associated to PLGA nanoparticles produced by different 876 
techniques. 877 
 878 
Table 8.Examples of peptide/protein-loaded PLGA nanoparticles obtained through different preparation methods: drug 879 





AE (%) LC (%) 
≤1 h burst / cumulative release 
(time) - pH medium 
Ref. 
Double emulsion - 
solvent 
evaporation 
BSA 70 - 80 0.7 - 0.8 n.a. / 80 % (28 d) pH 7.4 
[190] 
Insulin 70 - 80 3.5 - 4 n.a. / 20 % (28 d) pH 7.4 
Cyclosporine A 60 -90 n.a. 15 - 25 % / 70-90% (24 h) pH 7.4 [195] 
BSA 28 - 88 n.a. n.a. / 40 - 100 % (28 d) pH 7.4 [178] 
HSA 22 - 33 1.3 - 2.6 n.a. [196] 
Tetanus toxoid 31 - 37 n.a. 
n.a. / 7 - 18 % (1 d) pH 7.4 
<7 / 4 - 15 % (4 h) pH 1.2*/7.5* 
[170,
171] 
L-Asparaginase 15 - 40  1.8 - 4.9 n.a./15 - 95 % (21 d) pH 7.4 [189] 
Insulin n.a. n.a. n.a. / 70 % (40 d) pH n.a. 
[197] 
IGF-1 22 - 43 n.a. n.a. / 78 % (40 d) pH n.a. 
Emulsion - 
solvent diffusion 
BSA 4 - 60 
1 - 4 
theor. 




1 - 4 
theor. 
5 - 25 % / 10-30 % (14 d) pH 7.4 
Insulin 20 - 40 0.2 - 0.4 20 % / 80 % (14 h) pH 7.4 [181] 
PDGF-BB 87 0.01 40 % / 80 % (40 d) pH 7.4 
[182] 
FGF-2 68 0.01 40 % / 80 % (40  d) pH 7.4 
Nanoprecipitation 
Insulin 14 - 23 0.3 - 0.5 n.a.  
[184] 
Lysozyme 35 - 91 0.7 - 1.8 n.a.  
α-chymotrypsin 11 - 71 




Cyt-c 72 3.6 n. a. / 100 % (120 d) pH 7.3 
AE: association efficiency (100 x associated peptide mass / total peptide mass); BSA: bovine serum albumin; Cyt-c: horse 881 
heart cytochrome c; FGF-2: fibroblast growth factor; HAS: human serum albumin; IGF-1: insulin-like growth factor; IgG: 882 
immunoglobulin G; LC: loading capacity (100 x peptide mass /total formulation mass); n.a.: not applicable; PDGF-BB: 883 
platelet-derived growth factor; Ref.: references; theor.: theoretical; *Enzyme supplemented. 884 
 885 
2.b.2. Acrylic polymers-based nanoparticles 886 
 887 
Following the pioneering work of P. Speiser and co-workers on the association of antigens (human 888 
immunoglobulin G and tetanus toxoid) to polyacrylamide nanoparticles in 1976 [8], different types 889 
of acrylic polymers have been used to produce nanoparticles, including polyacrylic acid, 890 
polyacrylamides, polymethylmethacrylates and poly(alkylcyanoacrylates) [198]. These synthetic 891 















[199,200]. Among them, poly(alkylcyanoacrylates) (PACA) are the most commonly used for 893 
preparing nanoparticulate systems and, in particular, for the delivery of proteins. Their nitrile and 894 
ester groups are electron attractive functional groups and this property makes the vinyl carbon of 895 
the monomer really reactive, hence, able to polymerize in the presence of an initiator. Free 896 
radical, anionic or zwitterionic polymerization are the main approaches adopted so far for the 897 
production of PACA nanoparticles [200–202]. Overall, despite the early development and 898 
attention that these particles received in the past, only a few papers describing their use for 899 
protein delivery have been found in the literature.  900 
 901 
2.b.2.a. Preparation techniques 902 
 903 
Apart from the interfacial polymerization method, which has been mainly used for oily core 904 
nanocapsules production, and as such, it was described in the previous section (Section 2.a.4.a.), 905 
two main strategies (summarized in Table 9) have been described to synthesize polyacrylate-based 906 
nanostructures: the anionic polymerization and the free radical dispersion polymerization 907 
techniques. In both cases, the use organic solvents is avoided, being the main source of protein 908 
instability its potential reactivity with the monomer. 909 
 910 
Table 9. Main characteristics of the most commonly used techniques to form peptide/protein-loaded polyacrylate-based 911 
nanoparticles 912 







polymerization due to 









polymerization due to 
the generation of free 
radicals and crosslinking 
Undesirable reactions 
drug-monomers-
crosslinking agent / Free 
radicals / UV / Heat 
No + 
 913 
i) Anionic polymerization  914 
In this technique, the acrylic monomers, a stabilizer and an initiator (OH- in water) are necessary to 915 
form the nanoparticles. The monomers, which are poorly soluble in water, are emulsified into an 916 
acidic water solution (pH 2 - 4) containing the stabilizer (typically dextran). Once the droplets are 917 
formed, the monomer starts to polymerize thanks to the hydroxyl ions (OH-) present in the water 918 
phase (Fig.19). The acidic pH slows down the polymerization rate, thereby controlling the process 919 
of particles formation [133,201]. Proteins can be attached onto the surface of the particles, or 920 

















Figure 19. Schematic representation of the anionic-polymerization technique to produce polyacrylate-based 924 
nanoparticles 925 
 926 
ii) Free radical dispersion polymerization.  927 
Peppas and co-workers used this technique to obtain gel nanospheres through a photo- or 928 
thermal-initiated polymerization (Fig. 20). This technology involves the use of specific initiators as 929 
well as a crosslinking agent. The monomers (i.e. methacrylic acid, MAA and monomethylether 930 
monomethacrylate, PEGMA), the crosslinking agent (i.e. tetra (ethylene glycol) dimethacrylate) 931 
and the initiator (i.e., 1-Hydroxylcyclohexyl phenyl ketone) are solubilized in an aqueous phase. 932 
Once the initiator is activated (UV, heat), the formation of oligomers and crosslinks starts. Finally, 933 
since the polymer is not soluble in water, nuclei of polymerization are created leading to the 934 
formation of nanospheres (i.e. P(MAA-g-PEG)). Once the polymerization is completed, 935 
nanospheres are purified by repeated washing steps to remove the unreacted monomers and the 936 
association of the protein (i.e. insulin, OVA) is carried out in a subsequent incubation step 937 
[208,209].  938 
 939 
 940 
Figure 20. Schematic representation of the free radical dispersion polymerization technique to produce polyacrylate-941 
based gel nanospheres 942 
 943 
2.b.2.b. Characterization, peptide/protein loading, activity and release profile 944 
 945 
- Particle size distribution: in general, polyacrylate-based nanoparticles described in the literature 946 
have a size in the range of 50 nm and 500 nm and a negative surface charge [210–212]. Different 947 
parameters can affect the polymerization process and, as a consequence, the physicochemical 948 
properties of PACA nanoparticles. The most important parameter, which allows the control of the 949 
polymerization rate and, hence the particle formation is the pH, however, the monomer 950 
concentration also has a significant influence in this process. Finally, the temperature and the 951 

















- Peptide/protein loading and activity: Table 10 gives an overview of the properties of some 955 
protein/peptide-loaded polyacrylate-based nanoparticles formulations. The AE and LC values 956 
described in the literature are very variable, ranging between 3.5 and 95 % AE and up to 26 % LC 957 
[205,206,216]. Among the factors influencing the AE, the time at which the protein is added during 958 
the polymerization process has been found to be critical. For example, both insulin and GRF 959 
(growth hormone releasing factor) reached around 85 % AE when they were added to the 960 
polymerization medium 30 minutes after the process started [135,205]. 961 
 962 
As for the “in situ” polymerization method, the peptide/protein could undesirably work as a 963 
monomer during the polymerization procedure, which may result in its inactivation [206,217]. 964 
Apart from techniques like HPLC or enzymatic assays [203,217], direct in vivo efficacy of the 965 
formulation has often been used to test the integrity and activity of the loaded peptides/proteins 966 
[209]. 967 
 968 
- Peptide/protein release: the release of proteins from polyacrylate-based nanoparticles is mainly 969 
due to the bioerosion of the polymeric matrix [135]. Typically, these particles show an initial burst 970 
release, which can be buffered using additives. The presence of dextran into the formulation 971 
medium could, for example, delay the release of BSA from poly(α-butylcyanoacrylate) 972 
nanoparticles [206]. Protein release has also been shown to be strongly influenced by the type of 973 
PACA used. For example, the release of GRF was faster in the case of poly(isobutylcyanoacrylate), 974 
as compared to the case of poly(isohexylcyanoacrylate) nanoparticles. This was due to the 975 
different bioerosion rates of the two polymers [135]. In the particular case of the polyacrylate-976 
based gel nanospheres (acrylic acid (AA) or methacrylic acid (MAA), they were specifically 977 
designed to exhibit a pH-dependent swelling and, hence, release behavior [209]. This control could 978 
be achieved by adjusting the polymerization and crosslinking conditions.  979 
 980 
Table 10. Examples of peptide/protein-loaded polyacrylate-based nanoparticles prepared by anionic and free radical 981 





AE (%) LC (%) 





Insulin 87 n.a. n.a. [205] 
BSA 3.5 n.a. 15 - 55 % / 70- 90 % (14 d) pH 7.4 [206] 
SOD 7 - 33 n.a. n.a. 
[203] 
NR1 6 - 10 n.a. n.a. 





65 2.1 n.a. [208] 
93 - 95 7 10 - 80 % / 100 % (3 h) 1h pH 3 + 2 h pH 7 [209] 
OVA 51 26 0 % / 90 - 100 % (3 h) 1.5 h pH 3 + 2 h pH 7.4 [216] 
AE: association efficiency (100 x associated peptide mass / total peptide mass); BSA: bovine serum albumin; GRF: growth 983 
hormone releasing factor; LC: loading capacity (100 x peptide mass /total formulation mass); n.a.: not applicable; NR1: 984 
anti-glutamate N-methyl D-aspartate receptor 1 antibody; OVA: ovalbumin; Ref.: references; SOD: superoxide 985 
















2.b.3. Polysaccharide-based nanoparticles 988 
 989 
The most commonly employed polysaccharides for protein delivery purposes are chitosan, 990 
alginate, dextran and hyaluronic acid. Chitosan, a deacetylated form of chitin, is formed by 991 
repeated units of D-glucosamine and N-acetylglucosamine [41,42,43]. Alginate is a block co-992 
polymer made by α-guluronic acid (pKa 3.4) and β-D-mannuronic acid (pKa 3.6) residues linearly 993 
linked [220]. Like chitosan, it can be chemically modified on the acidic functional groups to obtain 994 
the desired properties [221,222]. Dextran is made by α (1→6) glucopyranoside units [223–225]. 995 
The hydroxyl groups are the main sites used for chemical modifications, with dextran sulfate as 996 
the most common modified form for drug delivery applications [226–228]. Finally, hyaluronic acid 997 
is a linear polysaccharide made by repeated units of the disaccharide formed by N-acetyl D–998 
glucosamine and D–glucuronic acid [229]. These natural polysaccharides have in common the 999 
property of being water-soluble; however their distinct chemistry results in different pKa and 1000 
functionality in terms of their potential interaction with different targets and their capacity to be 1001 
modified with different ligands. Among the polysaccharide-based nanoparticles described so far, 1002 
those made of chitosan were originally developed in our lab for the association of proteins 1003 
[15,230]. Since this discovery until now, chitosan nanoparticles have been classified as the 1004 
polymeric delivery nanoparticles that have received the greatest deal of attention. Overall, an 1005 
advantage of the techniques for the production of polysaccharide nanoparticles relies in the 1006 
mildness of the procedures [231–233], with the exception of the chemical crosslinking [234], 1007 
which may lead to the denaturation of the protein. 1008 
 1009 
Different techniques have been described until now to produce polysaccharide-based 1010 
nanoparticles and nanocomplexes, being the most commonly employed the ionic gelation and the 1011 
polyelectrolyte complexation. General specifications of the different preparation techniques are 1012 
presented in Table 11. 1013 
 1014 
Table 11. Characteristics of the most commonly used techniques to form polysaccharide-based nanoparticles containing 1015 
peptides/proteins 1016 






Gelation of the particles by 
ionic crosslinking 
Ionic interactions 
with the protein / 
Crosslinking agent 
No + + 
Polyelectrolyte 
complexation 
Ionic interaction between 
polymers of opposite charge 
Ionic interactions 
with the protein 
No + + 
 1017 
i) Ionic gelation/Ionic crosslinking  1018 
Our lab pioneered the development of chitosan nanoparticles using the ionic gelation/ionic 1019 
crosslinking technique [15,230], which has been later extended to other polysaccharides such as 1020 















polysaccharides can gel in aqueous solution in the presence of small ions and crosslinking agents 1022 
(Fig.21) [133,222,237]. The type of gelling agent is different based on the type of polysaccharide. 1023 
For example, in the case of chitosan, tripolyphosphate (TPP) is the most commonly crosslinking 1024 
agent employed, while in the case of alginates, the use of calcium salts (calcium chloride, calcium 1025 
sulfate, or calcium carbonate) is the most common gelation approach [15,222,236,238–241]. 1026 
 1027 
Alternatively, nanoparticles can be produced using a chemical cross-linking reaction. However, this 1028 
technique has not been almost explored for the association of proteins [234] due to the potential 1029 
chemical reactions with the loaded protein.  1030 
 1031 
 1032 
Figure 21. Schematic view of the ionic gelation/crosslinking technique to produce polysaccharide-based nanoparticles 1033 
 1034 
ii) Polyelectrolyte complexation 1035 
Polyelectrolytes complexes (PECs) are complexes resulting from the mixing of two oppositely 1036 
charged macromolecules (i.e., polyelectrolytes). A schematic representation of the procedure is 1037 
shown in Figure 22 [242,243]. The density of the charges and the charge distribution over the 1038 
polymeric chains, in addition to the concentration of the two polyelectrolytes are the main 1039 
parameters influencing the properties of the particles formed. The control of the ionic strength 1040 
and pH of the reaction medium, which influences the degree of ionization, is also fundamental for 1041 
the nanoparticles formation [244]. 1042 
 1043 
 1044 
Figure 22. Schematic view of the polyelectrolyte complexation technique to produce polysaccharide-based nanoparticles. 1045 
 1046 
2.b.3.b. Characterization, peptide/protein loading, activity and release profile 1047 
 1048 
- Particle size distribution: the ionic gelation/crosslinking is, among the techniques described 1049 
above, probably the one allowing a better control of the size. Indeed, in a report by our group 1050 
[245], intended to compare the ionic crosslinking vs. the ionic complexation of chitosan and pDNA, 1051 
we showed that the nanoparticles prepared by crosslinking of chitosan with TPP had a more 1052 















was attributed to the fact that the crosslinking with TPP led to the formation of nanogelled 1054 
particles with a round and more defined structure [246,247]. Overall, the main factors influencing 1055 
the particle size distribution are the ratio and the concentration of the ionically interacting species 1056 
[15,227]. 1057 
 1058 
- Peptide/protein loading and activity: in general, particles produced by gelation or complexation 1059 
are characterized by a high LC, which can reach values up to 50 % and AE values close to 100 % 1060 
[15,227,247,248]. The protein association efficiency is mainly affected by the number of 1061 
interacting species and their degree of ionization. For example the AE of insulin to chitosan 1062 
nanoparticles reached values close to 90 %, however the value decreased to 37 % in the case of 1063 
chitosan/glucomannan polyelectrolyte complexes [247]. This was attributed to the different pHs of 1064 
the protein solution and also to a competition between the protein and glucomannan for the 1065 
chitosan positive sites. A similar competition phenomenon was observed  for the basic peptide 1066 
salmon calcitonin, which was found to compete with protamine in its association to hyaluronic 1067 
acid/protamine nanoparticles [249]. These affinity/ionic competition phenomena have been taken 1068 
into account for the modulation of the LC. For example, the association efficiency of insulin to 1069 
chitosan-based nanoparticles could be increased from 66 % to 94 % when the anionic interacting 1070 
polymers were alginate and dextran sulfate respectively. This behaviour was explained due to the 1071 
strong ionic interactions between the insulin and the sulfate groups of dextran [250].  1072 
 1073 
The main source of instability for the loaded peptide/protein is, in both ionic gelation and 1074 
polyelectrolyte complexation, the possible ionic interaction between the peptide/protein and the 1075 
polymers/crosslinking agents, which could drive to protein denaturation [248,251,252]. 1076 
Additionally, the acidic pH often necessary to produce nanoparticles by ionic gelation (e.g. 1077 
chitosan nanoparticles) can destabilize or affect the peptide/protein activity (e.g. pH optimum of 1078 
enzymes) [253]. Both electrophoresis-based techniques (i.e. SDS-PAGE and Western blot) and 1079 
ELISA assays have been used to check if the peptide/protein integrity and activity were preserved 1080 
once included in polysaccharide-based nanoparticles[251,252,254]. Likewise, spectroscopy-based 1081 
techniques like FTIR have been used to study the interactions between the functional groups of 1082 
the peptide/protein and the polyelectrolytes [255]. In the case of enzymes, the activity was simply 1083 
evaluated through enzymatic activity assays [256]. Finally, in some cases, the activity was only 1084 
assessed after their in vivo administration [248,257]. 1085 
 1086 
- Peptide/protein release: from the point of view of drug release, nanoparticles produced by ionic 1087 
gelation or complexation normally show an ionic strength-dependent release profile, with an 1088 
initial burst release. In fact, the sensitivity of these systems to pH changes and to the presence of 1089 
ions, is one of their main drawbacks [228,247]. An example of this behavior has been observed for 1090 
insulin-loaded dextran sulfate/polyethylenimine (PEI) nanoparticles produced by complexation, 1091 
which completely released the peptide in PBS 50 mM after 5 minutes, while just the 65 % of the 1092 
















Among the formulation factors that can be modified in order to have a certain control of the 1095 
release process, the combination of different counteracting polymers and surfactants can be 1096 
highlighted. For example, we have shown that the release of BSA from chitosan nanoparticles 1097 
produced by ionic crosslinking was affected by the presence of poloxamer 188 in the formulation 1098 
[15,230]. Similarly, Sarmento et al compared the insulin release profile from alginate/chitosan and 1099 
dextran/chitosan nanoparticles [250]. They showed that the release of insulin was strongly 1100 
influenced by type of polymers used, being the interaction between the protein drug and the 1101 
polymers fundamental to control the release. These chitosan/alginate nanoparticles were shown 1102 
to have a pH-dependent release profile, suitable for the gastric and intestinal environment. In fact, 1103 
these systems were able to retain the protein at the low pH of the stomach, and release it in the 1104 
intestine, when the pH increased [236,258]. Swelling, dissociation, diffusion and erosion are 1105 
reported as the main mechanisms behind protein release from the nanoparticles made by ionic 1106 
gelation or polyelectrolyte complexation [227,259]. 1107 
 1108 
Overall, it could be concluded that polysaccharide-based nanoparticles are those leading to the 1109 
highest protein loading capacity, among those indicated in this review. The challenge that remains 1110 
associated to these nanoparticles is related to their limited capacity to control the release in 1111 
different physiologically relevant media. Nevertheless, the combination of different biomaterials 1112 
and surfactants are now seen as approaches to overcome this hurdle.  1113 
 1114 
Table 12 reports examples of peptides and proteins encapsulated into polysaccharide-based 1115 
nanoparticles synthesized by different strategies. 1116 
 1117 
Table 12. Examples of peptide/protein-loaded polysaccharide-based nanoparticles prepared by the different methods: 1118 





AE (%) LC (%) 
≤ 1 h burst / cumulative release 





87 - 97 19 - 55 
100 % / 100 % (2 h) pH 4/7 
80 - 100 % / 100 % (2 h) pH 6.4 
[248] 
40 - 90 
20 - 22 
theor.  




10 - 30 
16 - 21 
theor. 
10 -75 % / 10 - 75 % (2 h) pH 7.4 
BSA 5 - 80 10 - 50 n.a. / 30 - 100 % (8 d) pH 7 [15] 
Tetanus 
Toxoid 
50 10 n.a. [246] 
VEGF 32 - 94 0.04-0.34 80 % / > 90 % (24 h) pH 7 
[254] 
PDGF 27 - 54 0.05 -0.1 n.a. / > 90 % (7 d) pH 7 
Insulin 69 10 
95 % / 95 % (2 h) pH 1.2 




BSA 70 n.a. 40 - 60 % / 40 - 60 % (7 h) pH 7.4 [255] 
Insulin 66 - 94 5 - 13 
55 - 100 % / 55 - 100 % (2 h) pH 1.2 
















rHBsAg 90 - 95 2.5 - 5 n.a. [252] 
sCT 100 10 - 39 55 % / 70 - 80 % (24 h) pH 7.4 [249] 
TRIAL n.a. n.a. n.a. [257] 
ARH peptide 36 - 72 11 - 13 n.a. / 15 - 60 % (6 d) pH 7.4 [260] 
OVA 80 - 85 7 - 38 n.a. [220] 
AE: association efficiency (100 x associated peptide mass / total peptide mass); BSA: bovine serum albumin; INF-α: 1120 
interferon alpha; LC: loading capacity (100 x peptide mass /total formulation mass); n.a.: not applicable; OVA: 1121 
Ovalbumin; PDGF: platelet-derived growth factor; Ref.: references; rHBsAg: recombinant hepatitis B surface antigen; 1122 
sCT: salmon calcitonin; theor.: theoretical; TRIAL: tumor necrosis factor-related apoptosis inducing ligand; VEGF: 1123 
Vascular endothelial growth factor. 1124 
 1125 
2.b.4. Protein-based nanoparticles 1126 
Protein nanoparticles have been proposed for a long time as drug delivery systems due to their 1127 
low cost, easy production, low cytotoxicity and biodegradability [261,262]. A protein nanoparticle-1128 
based product for the delivery of paclitaxel (Abraxane®) has been approved by FDA and EMA, 1129 
generating a high interest around this kind of particles. Recent works related to protein 1130 
nanoparticles for protein delivery have been reported in literature, using gelatin, HSA, BSA, green 1131 
fluorescent protein (GFP) and silk fibroin as starting materials to produce the particles [261]. 1132 
 1133 
2.b.3.a. Preparation techniques 1134 
 1135 
The preparation method most commonly used to produce protein nanoparticles is the desolvation 1136 
technique, described below. 1137 
 1138 
i) Desolvation 1139 
An aqueous solution of both the therapeutic protein and the one used as a starting material to 1140 
produce the particles is prepared. A desolvating agent, like acetone, ethanol or dimethyl sulfoxide 1141 
(DMSO), is then slowly added to the proteins solution. After the desolvation process, 1142 
nanoaggregates of the proteins are formed and a crosslinking agent, usually glutaraldehyde, is 1143 
added, causing the formation of stable particles (Fig.23) [262,263]. Alternatively to the chemical 1144 
crosslinking, a coating with an ionic polymer (e.g., PEI) can be done to improve the stability of the 1145 

















Figure 23. Schematic view of the desolvation technique to produce protein nanoparticles 1149 
 1150 
2.b.3.b. Characterization, peptide/protein loading, activity, and release profile 1151 
 1152 
- Particle size distribution: the size of the protein-based nanoparticles, which usually ranges 1153 
between 150 and 400 nm, depends on parameters like the type of crosslinker and the crosslinking 1154 
time. Their surface charge depends on the pH of the media and the type of protein used to 1155 
produce the particles [263–266]. 1156 
 1157 
- Peptide/protein loading and activity: although the number of references describing the use of 1158 
protein nanoparticles for protein delivery is very low, in general high AE values are reported in 1159 
literature (Table 13). Furthermore, the presence of a polymer coating that helps to retain the 1160 
protein drug can also enhance the AE values of protein nanoparticles, as demonstrated for 1161 
albumin nanoparticles prepared by desolvation with PEI forming the polymer coating [264].  1162 
 1163 
The main drawback of the desolvation process is the use of organic solvents or crosslinking agents, 1164 
which could denaturate the peptide/protein structure, leading to protein inactivation. In this 1165 
regard, ELISA and enzymatic assays have been used to check if the peptide/protein activity was 1166 
retained after the nanoparticle formation [262,264,265]. 1167 
 1168 
- Peptide/protein release: a first burst release followed by a sustained release profile is usually 1169 
observed. The sustained release phase is associated to the degradation and dissolution of the 1170 
protein matrix. Therefore, the release is highly dependent on the type of protein forming the 1171 
matrix and also on its interaction with the protein cargo [264]. In the case of the PEI-coated BSA 1172 
nanoparticles developed by Zhang and co-workers, it was observed that a the layer of PEI could 1173 
reduce the undesired release of the protein drug (bone morphogenetic protein-2, BMP-2) from 70 1174 
% to 15 % in the first hour [264]. 1175 
 1176 



















AE (%) LC (%) 
≤ 1 h burst / cumulative release 
(time) - pH medium 
Ref. 
Desolvation 
BSA 0 - 89 n.a. 10 % / 90 % (150 h) pH 7.4  [253] 
β-galactosidase 80 - 95 n.a. 25 - 35 % / 40 - 60 % (300 h) pH 7.4  [262] 
BMP-2 > 90 n.a. 10 - 70 % / 50- 80 % (250 h) pH 7  [264] 
VEGF 100 n.a. 5 - 85 % / 50 - 100 % (20 d) pH 7.4  [265] 
HSA 80 10 n. a. / 25 % (400 h) pH 7.4  [266] 
AE: association efficiency (100 x associated peptide mass / total peptide mass); BMP - 2: bone morphogenetic protein - 2 1178 
BSA: bovine serum albumin; HSA: human serum albumin; LC: loading capacity (100 x peptide mass /total formulation 1179 
mass); n.a.: not applicable; Ref.: references; VEGF: Vascular endothelial growth factor. 1180 
 1181 
3. Current status of peptide/protein-loaded nanotechnologies 1182 
 1183 
The market of proteins and peptide drugs is growing exponentially, being proteins some of the top 1184 
selling drugs in the last years, particularly antibodies [267,268]. Despite their potential as 1185 
therapeutics, the feasibility of using protein drugs to treat patients is often hampered by their 1186 
short action, inadequate biodistribution and, in general, by the necessity of being administered by 1187 
injection [267]. As described in this review, numerous attempts have been made in order to 1188 
overcome these draw-backs through the use of drug delivery nanocarriers [269]. All these efforts 1189 
have been so far translated into the development of a few protein/peptide-based nanomedicines 1190 
that are now on the market or under clinical development [20]. Although several strategies have 1191 
been oriented towards making feasible the administration of proteins following a variety of 1192 
modalities of administration (ocular, pulmonary, nasal, transdermal) [267,270], the most advanced 1193 
developments are intended for oral administration and local delivery to the intestinal cavity 1194 
[271,272], or for systemic delivery upon oral [1,273] or parenteral administration[274]. 1195 
 1196 
With regard to the parenteral modality of administration, the use of nanodelivery carriers has 1197 
been found to improve the biodistribution and half-life of proteins (e.g. growth factors, vaccines), 1198 
thereby enhancing and prolonging their efficacy [274]. Among the nanocarriers investigated, 1199 
liposomes are the ones that have made their way to the market, in particular in the area of 1200 
vaccination (Table 14). For example, Inflexal® V is a 150 nm liposome formulation that contains 1201 
influenza virus antigens and is in the market since 1997 [275]. Another liposomal marketed 1202 
formulation is Mepact®, which contains the immune stimulant polypeptide drug mifamurtide, and 1203 
was commercialized in Europe in 2009 for the treatment of non-metastasizing resectable 1204 
osteosarcoma [276]. 1205 
 1206 
The possibility of administering peptide drugs by the oral route has attracted a great deal of 1207 
attention. Nevertheless, the aggressive environment of the gastrointestinal tract and the low 1208 
permeability of the intestinal epithelium make the administration of peptides/proteins through 1209 
this route a great challenge [277]. So far there are only two marketed oral peptide formulations 1210 
intended to achieve a systemic effect. These are Neoral®, a microemulsion formulation containing 1211 















simple tablet formulation of desmopressin that has a very limited but sufficient bioavailability (0.1 1213 
%) [279]. The efforts devoted in nanomedicine to facilitate the systemic delivery of peptide drugs 1214 
have been translated into a few formulations, which are now in clinical trials. Two of these 1215 
prototypes, which are made of inorganic particles, are in an early phase clinical development. 1216 
However, there is a liposomal formulation intended to deliver insulin to hepatocytes that is 1217 
currently in phase III clinical trials (Diasome Pharmaceuticals Inc.) [280]. In this case, the liposomes 1218 
contain a hepatocyte targeting agent (biotin-phosphatidylethanolamine) that facilitates their 1219 
uptake by hepatocytes upon their absorption through the hepatic-portal vein. It is also worth 1220 
noting that a number of companies are currently working in advanced preclinical phases on 1221 
nanoparticulate formulations for oral insulin delivery [281]. 1222 
 1223 
Table  14. Some selected examples of peptide/protein-loaded nanoformulations currently in the market or in clinical trials 1224 
for parenteral or oral administration. 1225 



















Mepact™ EMA 2009 [276] 






















Prophylaxis of organ 
rejection following 
organ transplant (Oral) 
Neoral® FDA 1995 [278] 
HPV: human papilloma virus; IM: intramuscular; IV: intravenous; n.a.: not applicable; Ref.: references; SEDDS: self-1226 
emulsifying drug delivery system; SC: subcutaneous. 1227 
 1228 
Other modalities of peptide/protein administration have also been explored so far with more 1229 
limited success. For example, the buccal administration has been explored for administering 1230 
peptides such as insulin. In particular, insulin-loaded PEG-b-PLA nanoparticles embedded into a 1231 
chitosan film were shown to increase the insulin permeation compared to pure insulin ex vivo 1232 
administered [283,284]. 1233 
 1234 
On the other hand, the pulmonary modality of administration has attracted particular attention 1235 
due to the huge surface area and high vascularization of the pulmonary mucosa as well as to the 1236 
highly permeable blood–alveolar barrier. Because of this, two insulin formulations have already 1237 
been commercialized, one of them withdrawn from the market in a short time [285]. In view of 1238 















help to overcome the limitations of the simple powders or solutions that reached the market 1240 
[270]. Nanocarriers such as liposomes and chitosan-based nanoparticles have been investigated 1241 
for pulmonary delivery of different drugs, such as insulin, calcitonin, leuprolide, enzymes, 1242 
cytokines and cyclosporine A [70,286–290]. For example, Al-Qadi et al. demonstrated a 1243 
pronounced hypoglycemic effect in normal rats after intratracheal administration of a powder 1244 
consisting of chitosan nanoparticles encapsulated in mannitol [286]. Similarly, Trapani et al., 1245 
developed heparin-loaded chitosan-based nanoparticles able to deliver the peptide to the lungs in 1246 
vivo to treat thromboembolic disorders [291]. Interestingly, phase I clinical studies have been 1247 
reached with a liposome-based formulation delivering interleukin-2 as therapeutic protein to treat 1248 
pulmonary metastases. The formulation was not toxic and showed a good pulmonary delivery 1249 
after inhalation, although further studies to test the efficacy of the therapy are not yet carried out 1250 
[289]. 1251 
 1252 
Our group has devoted significant efforts to the nasal administration of both peptides (i.e. insulin, 1253 
calcitonin) [119,248,292] and protein antigens [170,293]. Compared to other types of epithelia, 1254 
the nasal epithelium is rather porous and allows the transport of relatively large molecules 1255 
However, the nasal delivery of peptides/proteins is hampered by the efficient mucociliary 1256 
clearance existing in the nasal cavity, which also results in a high physiological variability [294]. We 1257 
pioneered the development of chitosan nanoparticles specifically designed for nasal insulin 1258 
delivery [248]. We have also investigated the potential of an array of nanocarriers made of PLGA-1259 
PEG and also of chitosan for the delivery of antigens, i.e. tetanus toxoid and hepatitis B 1260 
[153,170,293,294]. Finally, in this area it should be highlighted the development of a cyclosporine 1261 
A liposomal formulation whose phase I clinical trials were completed in 2015. The nasal 1262 
administration of this formulation notably improved the pharmacokinetics of the peptide without 1263 
showing any side effect [295,296] 1264 
 1265 
Other modalities of administration, i.e. the ocular and dermal routes have been explored as 1266 
potential ways to deliver peptide/protein drugs with the help of nanotechnology. For example, 1267 
cationic liposomes containing super oxide dismutase were used to treat UV-induced skin damages 1268 
in vivo, showing an enhanced transport of the protein through the skin when liposomes were 1269 
coupled with iontophoresis [297]. On the other hand, antibodies, growth factors, cyclosporine A 1270 
and antibiotics are just some examples of proteins and peptides delivered to the eye, following 1271 
different modalities of administration. For example, a cyclosporine A topical microemulsion 1272 
formulation was marketed in 2003 with interesting outcomes for the treatment of dry eye [298]. 1273 
Examples of preliminary preclinical developments include bevacizumab-loaded liposomes 1274 
associated to the protein annexin A5 [299] and bevacizumab-loaded chitosan nanoparticles, which 1275 
showed an enhanced anti-angiogenic effect after they were intravitreally injected in rats [300]. 1276 
 1277 
















In this review we disclose a number of technologies and biomaterials that can be potentially used 1280 
for the delivery of proteins. All these technologies and related biomaterials have specific 1281 
advantages and disadvantages. From the technological point of view, the use of solvent-free and 1282 
energy-free approaches, which do not require chemical reactions, are obviously desirable. Lipid 1283 
microemulsions, nanocapsules and polysaccharide-based nanoparticles are those nanosystems 1284 
that can be produced according to the mild indicated techniques. However, a limitation of the 1285 
lipid-based nanosystems is their limited loading capacity, whereas that of polysaccharide-based 1286 
nanoparticles relies on their limited stability and controlled release capacity. Overall, the 1287 
conclusion is that despite the important advances in the field, there is still a need to optimize the 1288 
nanocarriers’ properties for the desired peptidic drug through a rational design. In this regard, the 1289 
capability of the nanocarrier to efficiently entrap, appropriately release and preserve the integrity 1290 
of the protein/peptide loaded are so far the critical parameters to consider. Up until now, most 1291 
nanocarriers have been limited in their composition and architectural design. The current design 1292 
may need to imply the use of a combination of biomaterials conveniently organized within the 1293 
nanosystems internal and superficial structure. Hopefully, the use of these advanced nanocarriers 1294 
as delivery platforms will allow in the early future the successful administration of a wide variety 1295 
of potential therapeutic proteins/peptides. 1296 
 1297 
Acknowledgements 1298 
The authors acknowledge financial support given by Xunta de Galicia (Competitive Reference 1299 
Groups -FEDER Funds; Ref 2014/043), the TRANS-INT European Consortium, which has received 1300 
funding from the European Union’s Seventh Framework Programme for research, technological 1301 
development and demonstration under grant agreement No. 281035. Irene Santalices 1302 
acknowledges a predoctoral grant from the FPU program from the Ministry of Education, Culture 1303 
and Sports, MECD, Spain; Andrea Gonella acknowledges the support given by the European 1304 
Union's Horizon 2020 - Research and Innovation Framework Programme under the Marie 1305 
Sklodowska - Curie Grant agreement No. 642028 (NABBA). 1306 
 1307 
References 1308 
[1] T.A.S. Aguirre, D. Teijeiro-Osorio, M. Rosa, I.S. Coulter, M.J. Alonso, D.J. Brayden, Current 1309 
status of selected oral peptide technologies in advanced preclinical development and in 1310 
clinical trials, Adv. Drug Deliv. Rev. 106 (2016) 223–241. doi:10.1016/j.addr.2016.02.004. 1311 
[2] D.S. Pisal, M.P. Kosloski, S. V. Balu-Iyler, Delivery of therapeutic proteins, J. Pharm. Sci. 99 1312 
(2010) 2557–2575. doi:10.1002/jps.22054. 1313 
[3] C.F. Van Der Walle, O. Olejnik, An overview of the field of peptide and protein delivery, in: 1314 
C.F. Van Der Walle (Ed.), Pept. Protein Deliv., First, Academic Press, 2011: pp. 1–22. 1315 
doi:10.1016/b978-0-12-384935-9.10001-x. 1316 
[4] B.J. Bruno, G.D. Miller, C.S. Lim, Basics and recent advances in peptide and protein drug 1317 
delivery, Ther. Deliv. 4 (2013) 1443–1467. doi:10.4155/tde.13.104. 1318 
[5] K. Mg, Krenn V, F. Huebner, W. Wagner, Resch R, History and Possible Uses of 1319 
Nanomedicine Based on Nanoparticles and Nanotechnological Progress, J Nanomed 1320 
Nanotechnol. 64172 (2015) 3362157–7439. doi:10.4172/2157-7439.1000336. 1321 
[6] G. Gregoriadis, P. Leathwood, B.E. Ryman, Enzyme entrapment in liposomes, FEBS Lett. 14 1322 















[7] G. Gregoriadis, B.E. Ryman, Fate of protein containing liposomes injected into rats - An 1324 
approach to the treatment of storage diseases, Eur. J. Biochem. 24 (1972) 485–491. 1325 
doi:10.1111/j.1432-1033.1972.tb19710.x. 1326 
[8] G. Birrenbach, P.P. Speiser, Polymerized micelles and their use as adjuvants in immunology, 1327 
J. Pharm. Sci. 65 (1976) 1763–1766. doi:10.1002/jps.2600651217. 1328 
[9] C. Damge, C. Michel, M. Aprahamian, P. Couvreur, New approach for oral administration of 1329 
insulin with polyalkylcyanoacrylate nanocapsules as drug carrier, Diabetes. 37 (1988) 246–1330 
251. doi:10.2337/diab.37.2.246. 1331 
[10] S. Morel, M. Rosa Gasco, R. Cavalli, Incorporation in lipospheres of [D-Trp-6] LHRH, Int. J. 1332 
Pharm. 105 (1994) R1–R3. doi:10.1016/0378-5173(94)90466-9. 1333 
[11] S. Morel, E. Ugazio, R. Cavalli, M.R. Gasco, Thymopentin in solid lipid nanoparticles, Int. J. 1334 
Pharm. 132 (1996) 259–261. 1335 
[12] M.R. Gasco, Method for producing solid lipid microspheres having a narrow size 1336 
distribution, US5250236, 1993. 1337 
[13] A. Sánchez, J. Vila-Jato, M.J. Alonso, Development of biodegradable microspheres and 1338 
nanospheres for the controlled release of cyclosporin A, Int. J. Pharm. 99 (1993) 263–273. 1339 
doi:10.1016/0378-5173(93)90369-Q. 1340 
[14] P. Quellec, R. Gref, L. Perrin, E. Dellacherie, F. Sommer, J.M. Verbavatz, M.J. Alonso, Protein 1341 
encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical 1342 
characterization, J. Biomed. Mater. Res. 42 (1998) 45–54. doi:10.1002/(SICI)1097-1343 
4636(199810)42:1<45::AID-JBM7>3.0.CO;2-O. 1344 
[15] P. Calvo, C. Remuñán-López, J.L. Vila-Jato, M.J. Alonso, Novel hydrophilic chitosan-1345 
polyethylene oxide nanoparticles as protein carriers, J. Appl. Polym. Sci. 63 (1997) 125–132. 1346 
doi:10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4. 1347 
[16] D. Heinemann, S. Kalies, M. Schomaker, W. Ertmer, H. Murua Escobar, H. Meyer, T. Ripken, 1348 
Delivery of proteins to mammalian cells via gold nanoparticle mediated laser transfection, 1349 
Nanotechnology. 25 (2014) 245101. doi:10.1088/0957-4484/25/24/245101. 1350 
[17] Q. Mu, F.M. Kievit, R.J. Kant, G. Lin, M. Jeon, M. Zhang, Anti-HER2/neu peptide-conjugated 1351 
iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells, Naoscale. 1352 
7 (2015) 18010–18014. doi:10.1039/c5nr04867b. 1353 
[18] A. Antonucci, J. Kupis-Rozmyslowicz, A.A. Boghossian, Noncovalent protein and peptide 1354 
functionalization of single-walled carbon nanotubes for biodelivery and optical sensing 1355 
applications, ACS Appl. Mater. Interfaces. 9 (2017) 11321–11331. 1356 
doi:10.1021/acsami.7b00810. 1357 
[19] B. Zeng, H. Shi, Y. Liu, A versatile pHresponsive platform for intracellular protein delivery 1358 
using calcium phosphate nanoparticles, J. Mater. Chem. B. 3 (2015) 91159121. 1359 
doi:10.1039/c5tb01760b. 1360 
[20] V. Weissig, T.K. Pettinger, N. Murdock, Nanopharmaceuticals (part 1): products on the 1361 
market, Int. J. Nanomedicine. 9 (2014) 4357–4373. doi:10.2147/IJN.S46900. 1362 
[21] Nanomedicines Alliance, Nanomedicine drugs approved and in development, (2016). 1363 
https://media.wix.com/ugd/310180_b313086a455a43d394eb370ba944af7c.pdf (accessed 1364 
March 9, 2017). 1365 
[22] A. Hafner, J. Lovrić, G.P. Lakoš, I. Pepić, Nanotherapeutics in the EU: an overview on current 1366 
state and future directions, Int. J. Nanomedicine. 9 (2014) 1005–1023. 1367 
doi:10.2147/IJN.S55359. 1368 
[23] N. Desai, Challenges in development of nanoparticle-based therapeutics, AAPS J. 14 (2012) 1369 
282–295. doi:10.1208/s12248-012-9339-4. 1370 















the oral administration of biopharmaceutics, Nanomedicine. 11 (2016) 3009–3032. 1372 
doi:10.2217/nnm-2016-0265. 1373 
[25] Z. Niu, I. Conejos-Sánchez, B.T. Griffin, C.M. O’Driscoll, M.J. Alonso, Lipid-based 1374 
nanocarriers for oral peptide delivery, Adv. Drug Deliv. Rev. 106 (2016) 337–354. 1375 
doi:10.1016/j.addr.2016.04.001. 1376 
[26] P.L. Luisi, M. Giomini, M.P. Pileni, B.H. Robinson, Reverse micelles as hosts for proteins and 1377 
small molecules, Biochim. Biophys. Acta (BBA)-Reviews Biomembr. 947 (1988) 209–246. 1378 
doi:10.1016/0304-4157(88)90025-1. 1379 
[27] G. Sharma, K. Wilson, C.F. van der Walle, N. Sattar, J.R. Petrie, M.N.V. Ravi Kumar, 1380 
Microemulsions for oral delivery of insulin: design, development and evaluation in 1381 
streptozotocin induced diabetic rats, Eur. J. Pharm. Biopharm. 76 (2010) 159–169. 1382 
doi:10.1016/j.ejpb.2010.07.002. 1383 
[28] M. Garcia-Fuentes, D. Torres, M.J. Alonso, New surface-modified lipid nanoparticles as 1384 
delivery vehicles for salmon calcitonin, Int. J. Pharm. 296 (2005) 122–132. 1385 
doi:10.1016/j.ijpharm.2004.12.030. 1386 
[29] M. Garcia-Fuentes, C. Prego, D. Torres, M.J. Alonso, A comparative study of the potential of 1387 
solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers 1388 
for oral calcitonin delivery, Eur. J. Pharm. Sci. 25 (2005) 133–143. 1389 
doi:10.1016/j.ejps.2005.02.008. 1390 
[30] N. Zhang, Q. Ping, G. Huang, W. Xu, Y. Cheng, X. Han, Lectin-modified solid lipid 1391 
nanoparticles as carriers for oral administration of insulin, Int. J. Pharm. 327 (2006) 153–1392 
159. doi:10.1016/j.ijpharm.2006.07.026. 1393 
[31] F. Hintzen, G. Perera, S. Hauptstein, C. Müller, F. Laffleur, A. Bernkop-Schnürch, In vivo 1394 
evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin, 1395 
Int. J. Pharm. 472 (2014) 20–26. doi:10.1016/j.ijpharm.2014.05.047. 1396 
[32] J.D. Meyer, M.C. Manning, Hydrophobic ion pairing: altering the solubility properties of 1397 
biomolecules, Pharm. Res. 15 (1998) 188–193. doi:10.1023/A:1011998014474. 1398 
[33] G. Zhang, T. Wang, L. Gao, D. Quan, Oral delivery of oil-based formulation for a novel 1399 
synthetic cationic peptide of GnRH (gonadotropin-releasing hormone) antagonist for 1400 
prostate cancer treatment, Int. J. Pharm. 450 (2013) 138–144. 1401 
doi:10.1016/j.ijpharm.2013.04.047. 1402 
[34] C. Zheng, M. Duan, H. Ma, H. Zhong, Zheng, Method for preparation of orally administrated 1403 
insulin formulation, US 7018980 B2, 2006. 1404 
[35] E. Ma, H. Ma, Z. Liu, C. Zheng, M. Duan, In vitro and in vivo evaluation of a novel oral insulin 1405 
formulation, Acta Pharmacol. Sin. 27 (2006) 1382–1388. doi:10.1111/j.1745-1406 
7245.2006.00424.x. 1407 
[36] A.D. Bangham, R.W. Horne, Negative staining of phospholipids and their structural 1408 
modification by surface-active agents as observed in the electron microscope, J. Mol. Biol. 8 1409 
(1964) 660–668. doi:10.1016/S0022-2836(64)80115-7. 1410 
[37] A.D. Bangham, M.M. Standish, J.C. Watkins, Diffusion of univalent ions across the lamellae 1411 
of swollen phospholipids, J. Mol. Biol. 13 (1965) 238–252. doi:10.1016/S0022-1412 
2836(65)80093-6. 1413 
[38] D. Ibraheem, A. Elaissari, H. Fessi, Administration strategies for proteins and peptides, Int. J. 1414 
Pharm. 477 (2014) 578–589. doi:10.1016/j.ijpharm.2014.10.059. 1415 
[39] E. Elizondo, E. Moreno, I. Cabrera, A. Córdoba, S. Sala, J. Veciana, N. Ventosa, Liposomes 1416 
and other vesicular systems: structural characteristics, methods of preparation, and use in 1417 
nanomedicine, 2011. doi:10.1016/B978-0-12-416020-0.00001-2. 1418 















Drug Deliv. 9 (2012) 1489–1503. doi:10.1517/17425247.2012.735658. 1420 
[41] F. Ahmed, D.E. Discher, Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-1421 
triggered controlled release vesicles, J. Control. Release. 96 (2004) 37–53. 1422 
doi:10.1016/j.jconrel.2003.12.021. 1423 
[42] B.M. Discher, Y.-Y. Won, D.S. Ege, J.C.-M. Lee, F.S. Bates, D.E. Discher, D.A. Hammer, 1424 
Polymersomes: tough vesicles made from diblock copolymers, Science (80-. ). 284 (1999) 1425 
1143–1146. doi:10.1126/science.284.5417.1143. 1426 
[43] Z. Li, J. Chen, W. Sun, Y. Xu, Investigation of archaeosomes as carriers for oral delivery of 1427 
peptides, Biochem. Biophys. Res. Commun. 394 (2010) 412–417. 1428 
doi:10.1016/j.bbrc.2010.03.041. 1429 
[44] A. Pardakhty, J. Varshosaz, A. Rouholamini, In vitro study of polyoxyethylene alkyl ether 1430 
niosomes for delivery of insulin, Int. J. Pharm. 328 (2007) 130–141. 1431 
doi:10.1016/j.ijpharm.2006.08.002. 1432 
[45] A. Madni, M. Sarfraz, M. Rehman, M. Ahmad, N. Akhtar, S. Ahmad, N. Tahir, S. Ijaz, R. Al-1433 
Kassas, R. Löbenberg, Liposomal drug delivery: a versatile platform for challenging clinical 1434 
applications, J. Pharm. Pharm. Sci. 17 (2014) 401–426. doi:10.18433/J3CP55. 1435 
[46] M.R. Mozafari, Liposomes : an overview of manufacturing techniques, Cell. Mol. Biol. Lett. 1436 
10 (2005) 711–719. 1437 
[47] A. Laouini, C. Jaafar-Maalej, I. Limayem-Blouza, S. Sfar, C. Charcosset, H. Fessi, Preparation, 1438 
characterization and applications of liposomes: state of the art, J. Colloid Sci. Biotechnol. 1 1439 
(2012) 147–168. doi:10.1166/jcsb.2012.1020. 1440 
[48] A.K. Agrawal, H. Harde, K. Thanki, S. Jain, Improved stability and antidiabetic potential of 1441 
insulin containing folic acid functionalized polymer stabilized multilayered liposomes 1442 
following oral administration, Biomacromolecules. 15 (2014) 350–360. 1443 
doi:10.1021/bm401580k. 1444 
[49] Y.P. Patil, S. Jadhav, Novel methods for liposome preparation, Chem. Phys. Lipids. 177 1445 
(2014) 8–18. doi:10.1016/j.chemphyslip.2013.10.011. 1446 
[50] A. Badiee, M.R. Jaafari, A. Khamesipour, Leishmania major: immune response in BALB/c 1447 
mice immunized with stress-inducible protein 1 encapsulated in liposomes, Exp. Parasitol. 1448 
115 (2007) 127–134. doi:10.1016/j.exppara.2006.07.002. 1449 
[51] V.P. Torchilin, R. Rammohan, V. Weissig, T.S. Levchenko, TAT peptide on the surface of 1450 
liposomes affords their efficient intracellular delivery even at low temperature and in the 1451 
presence of metabolic inhibitors, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8786–8791. 1452 
doi:10.1073/pnas.151247498. 1453 
[52] S. Murakami, T. Ono, S. Sakai, H. Ijima, K. Kawakami, Effect of diglucosamine on the 1454 
entrapment of protein into liposomes, J. Liposome Res. 16 (2006) 103–112. 1455 
doi:10.1080/08982100600680667. 1456 
[53] T. Goto, M. Morishita, K. Nishimura, M. Nakanishi, A. Kato, J. Ehara, K. Takayama, Novel 1457 
mucosal insulin delivery systems based on fusogenic liposomes, Pharm. Res. 23 (2006) 384–1458 
391. doi:10.1007/s11095-005-9175-7. 1459 
[54] C. Kirby, G. Gregoriadis, Dehydration-rehydration vesicles: a simple method for high yield 1460 
drug entrapment in liposomes, Nat. Biotechnol. 2 (1984) 979–984. doi:10.1038/nbt1184-1461 
979. 1462 
[55] M.A. García-Santana, J. Duconge, M.E. Sarmiento, M.E. Lanio-Ruíz, M. Becquer, L. 1463 
Izquierdo, A. Acosta-Domínguez, Biodistribution of liposome-entrapped human gamma-1464 
globulin, Biopharnaceutics Drug Dispos. 27 (2006) 275–283. doi:10.1002/bdd.511. 1465 
















[57] M.A. Kisel, L.N. Kulik, I.S. Tsybovsky, A.P. Vlasov, M.S. Vorob’yov, E.A. Kholodova, Z. V. 1468 
Zabarovskaya, Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: 1469 
studies in the rat, Int. J. Pharm. 216 (2001) 105–114. doi:10.1016/S0378-5173(01)00579-8. 1470 
[58] N. chitosan coated liposomes for oral protein drug delivery Kowapradit, JariyaMethylated 1471 
N-(4-N, A. Apirakaramwong, T. Ngawhirunpat, T. Rojanarata, W. Sajomsang, P. Opanasopit, 1472 
Methylated N-(4-N,N-dimethylaminobenzyl) chitosan coated liposomes for oral protein 1473 
drug delivery, Eur. J. Pharm. Sci. 47 (2012) 359–366. doi:10.1016/j.ejps.2012.06.020. 1474 
[59] J. Colletier, B. Chaize, M. Winterhalter, D. Fournier, Protein encapsulation in liposomes: 1475 
efficiency depends on interactions between protein and phospholipid bilayer, BMC 1476 
Biotechnol. 2 (2002). doi:10.1186/1472-6750-2-9. 1477 
[60] J.S. Dua, A.C. Rana, A.K. Bhandari, Liposome: method of preparation and applications, Int. J. 1478 
Pharm. Stud. Res. 3 (2012) 14–20. 1479 
[61] T. Wang, G.G.M. D’Souza, D. Bedi, O.A. Fagbohun, L. Prasanna Potturi, B. Papahadjopoulos-1480 
sternberg, V.A. Petrenko, V.P. Torchilin, Enhanced binding and killing of target tumor cells 1481 
by drugloaded liposomes modified with tumor-specific phage fusion coat protein, 1482 
Nanomedicine. 5 (2010) 563–574. doi:10.2217/nnm.10.30. 1483 
[62] M. Anderson, A. Omri, The effect of different lipid components on the in vitro stability and 1484 
release kinetics of liposome formulations, Drug Deliv. 11 (2004) 33–39. 1485 
doi:10.1080/10717540490265243. 1486 
[63] K. Iwanaga, S. Ono, K. Narioka, M. Kakemi, K. Morimoto, S. Yamashita, Y. Namba, O. Naoto, 1487 
Application of surface-coated liposomes for oral delivery of peptide: effects of coating the 1488 
liposome’s surface on the GI transit of insulin, J. Pharm. Sci. 88 (1999) 248–252. 1489 
doi:10.1021/js980235x. 1490 
[64] E.L.S. Carvalho, A. Grenha, C. Remuñán-López, M.J. Alonso, B. Seijo, Mucosal delivery of 1491 
liposome-chitosan nanoparticle complexes, in: Methods Enzymol., Academic Press, 2009: 1492 
pp. 289–312. doi:10.1016/S0076-6879(09)65015-1. 1493 
[65] V.J. Mohanraj, T.J. Barnes, C.A. Prestidge, Silica nanoparticle coated liposomes: a new type 1494 
of hybrid nanocapsule for proteins, Int. J. Pharm. 392 (2010) 285–293. 1495 
doi:10.1016/j.ijpharm.2010.03.061. 1496 
[66] N. Zhang, Q.N. Ping, G.H. Huang, W.F. Xu, Investigation of lectin-modified insulin liposomes 1497 
as carriers for oral administration, Int. J. Pharm. 294 (2005) 247–259. 1498 
doi:10.1016/j.ijpharm.2005.01.018. 1499 
[67] A. Makhlof, S. Fujimoto, Y. Tozuka, H. Takeuchi, In vitro and in vivo evaluation of WGA-1500 
carbopol modified liposomes as carriers for oral peptide delivery, Eur. J. Pharm. Biopharm. 1501 
77 (2011) 216–224. doi:10.1016/j.ejpb.2010.12.008. 1502 
[68] M. Carafa, C. Marianecci, V. Annibaldi, A. Di Stefano, P. Sozio, E. Santucci, Novel O-1503 
palmitoylscleroglucan-coated liposomes as drug carriers: development, characterization 1504 
and interaction with leuprolide, Int. J. Pharm. 325 (2006) 155–162. 1505 
doi:10.1016/j.ijpharm.2006.06.040. 1506 
[69] N. Arulsudar, N. Subramanian, P. Mishra, K. Chuttani, R.K. Sharma, R.S.R. Murthy, 1507 
Preparation, characterization, and biodistribution study of technetium-99m-labeled 1508 
leuprolide acetate-loaded liposomes in ehrlich ascites tumor-bearing mice, AAPS J. 6 (2004) 1509 
45–56. doi:10.1208/ps060105. 1510 
[70] A. Shahiwala, A. Misra, A preliminary pharmacokinetic study of liposomal leuprolide dry 1511 
powder inhaler: a technical note, AAPS PharmSciTech. 6 (2005) E482–E486. 1512 
doi:10.1208/pt060360. 1513 
[71] C. Schwarz, W. Mehnert, J.S. Lucks, R.H. Müller, Solid lipid nanoparticles (SLN) for 1514 















Release. 30 (1994) 83–96. doi:10.1016/0168-3659(94)90047-7. 1516 
[72] R.H. Müller, K. Mäder, S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery - 1517 
a review of the state of the art, Eur. J. Pharm. Biopharm. 50 (2000) 161–177. 1518 
doi:10.1016/S0939-6411(00)00087-4. 1519 
[73] V. Jannin, E. Dellera, S. Chevrier, Y. Chavant, C. Voutsinas, C. Bonferoni, F. Demarne, In vitro 1520 
lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic 1521 
extract, Drug Dev. Ind. Pharm. 41 (2015) 1582–1588. doi:10.3109/03639045.2014.972412. 1522 
[74] S.M. Martins, B. Sarmento, D. Ferreira, E.B. Souto, Lipid-based colloidal carriers for peptide 1523 
and protein delivery — Liposomes versus lipid nanoparticles, Int. J. Nanomedicine. 2 (2007) 1524 
595–607. 1525 
[75] L.J. Penkler, R.H. Müller, S.A. Runge, V. Ravelli, Pharmaceutical cyclosporin formulation 1526 
with improved biopharmaceutical properties, improved physical quality and greater 1527 
stability, and method for producing said formulation, US 6551619 B1, 2003. 1528 
[76] A.J. Almeida, S. Runge, R.H. Müller, Peptide-loaded solid lipid nanoparticles (SLN): influence 1529 
of production parameters, Int. J. Pharm. 149 (1997) 255–265. doi:10.1016/S0378-1530 
5173(97)04885-0. 1531 
[77] B. Sjöström, B. Bergenståhl, Preparation of submicron drug particles in lecithin-stabilized 1532 
o/w emulsions I. Model studies of the precipitation of cholesteryl acetate, Int. J. Pharm. 88 1533 
(1992) 53–62. doi:10.1016/0378-5173(93)90013-6. 1534 
[78] M. García-Fuentes, D. Torres, M.J. Alonso, Design of lipid nanoparticles for the oral delivery 1535 
of hydrophilic macromolecules, Colloids Surfaces B Biointerfaces. 27 (2003) 159–168. 1536 
doi:10.1016/S0927-7765(02)00053-X. 1537 
[79] F.Q. Hu, Y. Hong, H. Yuan, Preparation and characterization of solid lipid nanoparticles 1538 
containing peptide, Int. J. Pharm. 273 (2004) 29–35. doi:10.1016/j.ijpharm.2003.12.016. 1539 
[80] H. Yuan, S.-P. Jiang, Y.-Z. Du, J. Miao, X.-G. Zhang, F.-Q. Hu, Strategic approaches for 1540 
improving entrapment of hydrophilic peptide drugs by lipid nanoparticles, Colloids Surfaces 1541 
B Biointerfaces. 70 (2009) 248–253. doi:10.1016/j.colsurfb.2008.12.031. 1542 
[81] S.P. Sellers, G.S. Clark, R.E. Sievers, J.F. Carpenter, Dry powders of stable protein 1543 
formulations from aqueous solutions prepared using supercritical CO2-assisted 1544 
aerosolization, J. Pharm. Sci. 90 (2001) 785–797. doi:10.1002/jps.1032. 1545 
[82] S. Liedtke, S. Wissing, R.H. Müller, K. Mäder, Influence of high pressure homogenisation 1546 
equipment on nanodispersions characteristics, Int. J. Pharm. 196 (2000) 183–185. 1547 
doi:10.1016/S0378-5173(99)00417-2. 1548 
[83] W. Mehnert, M. Mäder, Solid lipid nanoparticles: production, characterization and 1549 
applications, Adv. Drug Deliv. Rev. 47 (2001) 165–196. doi:10.1016/s0169-409x(01)00105-1550 
3. 1551 
[84] E. Ugazio, R. Cavalli, M.R. Gasco, Incorporation of cyclosporin A in solid lipid nanoparticles 1552 
(SLN), Int. J. Pharm. 241 (2002) 341–344. doi:10.1016/S0378-5173(02)00268-5. 1553 
[85] M. Muchow, P. Maincent, R.H. Müller, Lipid nanoparticles with a solid matrix (SLN®, NLC®, 1554 
LDC®) for oral drug delivery, Drug Dev. Ind. Pharm. 34 (2008) 1394–1405. 1555 
doi:10.1080/03639040802130061. 1556 
[86] C. Chen, T. Fan, Y. Jin, Z. Zhou, Y. Yang, X. Zhu, Z. Zhang, Q. Zhang, Y. Huang, Orally 1557 
delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle–double 1558 
emulsion method via the combined use of different solid lipids, Nanomedicine. 8 (2013) 1559 
1085–1100. doi:10.2217/nnm.12.141. 1560 
[87] J. Liu, T. Gong, C. Wang, Z. Zhong, Z. Zhang, Solid lipid nanoparticles loaded with insulin by 1561 
sodium cholate-phosphatidylcholine-based mixed micelles: preparation and 1562 















[88] A.J. Almeida, E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and 1564 
proteins, Adv. Drug Deliv. Rev. 59 (2007) 478–490. doi:10.1016/j.addr.2007.04.007. 1565 
[89] S. Salmaso, N. Elvassore, A. Bertucco, P. Caliceti, Production of solid lipid submicron 1566 
particles for protein delivery using a novel supercritical gas-assisted melting atomization 1567 
process, J. Pharm. Sci. 98 (2009) 640–650. doi:10.1002/jps.21434. 1568 
[90] R.H. Müller, S. Runge, V. Ravelli, W. Mehnert, A.F. Thünemann, E.B. Souto, Oral 1569 
bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals, Int. 1570 
J. Pharm. 317 (2006) 82–89. doi:10.1016/j.ijpharm.2006.02.045. 1571 
[91] S. Salmaso, S. Bersani, N. Elvassore, A. Bertucco, P. Caliceti, Biopharmaceutical 1572 
characterisation of insulin and recombinant human growth hormone loaded lipid 1573 
submicron particles produced by supercritical gas micro-atomisation, Int. J. Pharm. 379 1574 
(2009) 51–58. doi:10.1016/j.ijpharm.2009.06.014. 1575 
[92] J.H. Schulman, W. Stoeckenius, L.M. Prince, Mechanism of formation and structure of micro 1576 
emulsions by electron microscopy, J. Phys. Chem. 63 (1959) 1677–1680. 1577 
doi:10.1021/j150580a027. 1578 
[93] D.J. McClements, Nanoemulsions versus microemulsions: terminology, differences, and 1579 
similarities, Soft Matter. 8 (2012) 1719–1729. doi:10.1039/c2sm06903b. 1580 
[94] N. Anton, T.F. Vandamme, Nano-emulsions and micro-emulsions: Clarifications of the 1581 
critical differences, Pharm. Res. 28 (2011) 978–985. doi:10.1007/s11095-010-0309-1. 1582 
[95] N. Anton, J.P. Benoit, P. Saulnier, Design and production of nanoparticles formulated from 1583 
nano-emulsion templates - A review, J. Control. Release. 128 (2008) 185–199. 1584 
doi:10.1016/j.jconrel.2008.02.007. 1585 
[96] D.J. McClements, Edible nanoemulsions: fabrication, properties, and functional 1586 
performance, Soft Matter. 7 (2011) 2297–2316. doi:10.1039/C0SM00549E. 1587 
[97] D.J. McClements, Nanoemulsion-based oral delivery systems for lipophilic bioactive 1588 
components: nutraceuticals and pharmaceuticals, Ther. Deliv. 4 (2013) 841–857. 1589 
doi:10.4155/tde.13.46. 1590 
[98] B. Abismail, J.P. Canselier, A.M. Wilhelm, H. Delmas, C. Gourdon, Emulsification by 1591 
ultrasound: drop size distribution and stability, Ultrason. Sonochem. 6 (1999) 75–83. 1592 
doi:10.1016/S1350-4177(98)00027-3. 1593 
[99] J.M. Asua, Challenges for industrialization of miniemulsion polymerization, Prog. Polym. Sci. 1594 
39 (2014) 1797–1826. doi:10.1016/j.progpolymsci.2014.02.009. 1595 
[100] P. Walstra, Principles of emulsion formation, Chem. Eng. Sci. 48 (1993) 333–349. 1596 
doi:10.1016/0009-2509(93)80021-H. 1597 
[101] K. Shinoda, H. Saito, The stability of O/W type emulsions as functions of temperature and 1598 
the HLB of emulsifiers: the emulsification by PIT-method, J. Colloid Interface Sci. 30 (1969) 1599 
258–263. doi:10.1016/S0021-9797(69)80012-3. 1600 
[102] K. Shinoda, H. Saito, The effect of temperature on the phase equilibria and the types of 1601 
dispersions of the ternary system composed of water, cyclohexane, and nonionic 1602 
surfactant, J. Colloid Interface Sci. 26 (1968) 70–74. doi:10.1016/0021-9797(68)90273-7. 1603 
[103] J.C. Leroux, E. Allémann, E. Doelker, R. Gurny, New approach for the preparation of 1604 
nanoparticles by an emulsification-diffusion method, Eur. J. Pharm. Biopharm. 41 (1995) 1605 
14–18. 1606 
[104] S. Magdassi, L. Spernath, Method for the preparation of nanoparticles from 1607 
nenoemulsions, US 2011/0135734 A1, 2011. 1608 
[105] C.A. Miller, Spontaneous emulsification produced by diffusion - A review, Colloids and 1609 
Surfaces. 29 (1988) 89–102. doi:10.1016/0166-6622(88)80173-2. 1610 















Pharm. 377 (2009) 142–147. doi:10.1016/j.ijpharm.2009.05.014. 1612 
[107] D.J. McClements, J. Rao, Food-grade nanoemulsions: formulation, fabrication, properties, 1613 
performance, biological fate, and potential toxicity, Crit. Rev. Food Sci. Nutr. 51 (2011) 285–1614 
330. doi:10.1080/10408398.2011.559558. 1615 
[108] C. Qian, D.J. McClements, Formation of nanoemulsions stabilized by model food-grade 1616 
emulsifiers using high-pressure homogenization: factors affecting particle size, Food 1617 
Hydrocoll. 25 (2011) 1000–1008. doi:10.1016/j.foodhyd.2010.09.017. 1618 
[109] T.S.H. Leong, T.J. Wooster, S.E. Kentish, M. Ashokkumar, Minimising oil droplet size using 1619 
ultrasonic emulsification, Ultrason. Sonochem. 16 (2009) 721–727. 1620 
doi:10.1016/j.ultsonch.2009.02.008. 1621 
[110] L. Lee, I.T. Norton, Comparing droplet breakup for a high-pressure valve homogeniser and a 1622 
microfluidizer for the potential production of food-grade nanoemulsions, J. Food Eng. 114 1623 
(2013) 158–163. doi:10.1016/j.jfoodeng.2012.08.009. 1624 
[111] A.H. Saberi, Y. Fang, D.J. McClements, Fabrication of vitamin E-enriched nanoemulsions: 1625 
factors affecting particle size using spontaneous emulsification, J. Colloid Interface Sci. 391 1626 
(2013) 95–102. doi:10.1016/j.jcis.2012.08.069. 1627 
[112] C.W. Pouton, C.J.H. Porter, Formulation of lipid-based delivery systems for oral 1628 
administration: materials, methods and strategies, Adv. Drug Deliv. Rev. 60 (2008) 625–1629 
637. doi:10.1016/j.addr.2007.10.010. 1630 
[113] A.A. Date, N. Desai, R. Dixit, M. Nagarsenker, Self-nanoemulsifying drug delivery systems: 1631 
formulation insights, applications and advances, Nanomedicine. 5 (2010) 1595–1616. 1632 
doi:10.2217/nnm.10.126. 1633 
[114] A.S. Cunha, J.L. Grossiord, F. Puisieux, M. Seiller, Insulin in w/o/w multiple emulsions: 1634 
preparation, characterization and determination of stability towards proteases in vitro, J 1635 
Microencapsul. 14 (1997) 311–319. doi:10.3109/02652049709051135. 1636 
[115] A. Silva-Cunha, J.L. Grossiord, F. Puisieux, M. Seiller, W/O/W multiple emulsions of insulin 1637 
containing a protease inhibitor and an absorption enhancer: preparation, characterization 1638 
and determination of stability towards proteases in vitro, Int. J. Pharm. 158 (1997) 79–89. 1639 
doi:10.1016/S0378-5173(97)00249-4. 1640 
[116] A. Elsayed, M. Al Remawi, N. Qinna, A. Farouk, A. Badwan, Formulation and 1641 
characterization of an oily-based system for oral delivery of insulin, Eur. J. Pharm. 1642 
Biopharm. 73 (2009) 269–279. doi:10.1016/j.ejpb.2009.06.004. 1643 
[117] T. Karamanidou, K. Karidi, V. Bourganis, K. Kontonikola, O. Kammona, C. Kiparissides, 1644 
Effective incorporation of insulin in mucus permeating self-nanoemulsifying drug delivery 1645 
systems, Eur. J. Pharm. Biopharm. 97 (2015) 223–229. doi:10.1016/j.ejpb.2015.04.013. 1646 
[118] T. Trenktrog, B.W. Müller, Preparation and characterization of a peptide containing w/o 1647 
emulsion, Int. J. Pharm. 123 (1995) 199–207. doi:10.1016/0378-5173(95)00057-P. 1648 
[119] C. Prego, D. Torres, M.J. Alonso, Chitosan nanocapsules: a new carrier for nasal peptide 1649 
delivery, J. Drug Deliv. Sci. Technol. 16 (2006) 331–337. doi:10.1016/S1773-2247(06)50061-1650 
9. 1651 
[120] D. Liu, T. Kobayashi, S. Russo, F. Li, S.E. Plevy, T.M. Gambling, J.L. Carson, R.J. Mumper, In 1652 
vitro and in vivo evaluation of a water-in-oil microemulsion system for enhanced peptide 1653 
intestinal delivery, AAPS J. 15 (2013) 288–298. doi:10.1208/s12248-012-9441-7. 1654 
[121] P.P. Constantinides, S.H. Yiv, Particle size determination of phase-inverted water-in-oil 1655 
microemulsions under different dilution and storage conditions, Int. J. Pharm. 115 (1995) 1656 
225–234. doi:10.1016/0378-5173(94)00272-7. 1657 
[122] S. Gupta, R. Kesarla, A. Omri, Formulation strategies to improve the bioavailability of poorly 1658 















(2013) 1–16. doi:10.1155/2013/848043. 1660 
[123] C. Prego, M. García, D. Torres, M.J. Alonso, Transmucosal macromolecular drug delivery, J. 1661 
Control. Release. 101 (2005) 151–162. doi:10.1016/j.jconrel.2004.07.030. 1662 
[124] T. Gonzalo, G. Lollo, M. Garcia-Fuentes, D. Torres, J. Correa, R. Riguera, E. Fernandez-1663 
Megia, P. Calvo, P. Avilés, M.J. Guillén, M.J. Alonso, A new potential nano-oncological 1664 
therapy based on polyamino acid nanocapsules, J. Control. Release. 169 (2013) 10–16. 1665 
doi:10.1016/j.jconrel.2013.03.037. 1666 
[125] L. Guo, E. Ma, H. Zhao, Y. Long, C. Zheng, M. Duan, Preliminary evaluation of a novel oral 1667 
delivery system for rhPTH1-34: in vitro and in vivo, Int. J. Pharm. 420 (2011) 172–179. 1668 
doi:10.1016/j.ijpharm.2011.08.029. 1669 
[126] S.T. Dogru, S. Çalis, F. Öner, Oral multiple w/o/w emulsion formulation of a peptide salmon 1670 
calcitonin: in vitro-in vivo evaluation, J. Clin. Pharm. Ther. 25 (2000) 435–443. 1671 
doi:10.1046/j.1365-2710.2000.00306.x. 1672 
[127] S. Hirsjärvi, Y. Qiao, A. Royere, J. Bibette, J.P. Benoit, Layer-by-layer surface modification of 1673 
lipid nanocapsules, Eur. J. Pharm. Biopharm. 76 (2010) 200–207. 1674 
doi:10.1016/j.ejpb.2010.07.010. 1675 
[128] P. Calvo, A. Sánchez, J. Martínez, M.I. López, M. Calonge, J.C. Pastor, M.J. Alonso, Polyester 1676 
nanocapsules as new topical ocular delivery systems for cyclosporin A, Pharm. Res. 13 1677 
(1996) 311–315. doi:10.1023/A:1016015803611. 1678 
[129] L.N. Thwala, A. Beloqui, N.S. Csaba, D. González-Touceda, S. Tovar, C. Dieguez, M.J. Alonso, 1679 
V. Préat, The interaction of protamine nanocapsules with the intestinal epithelium: a 1680 
mechanistic approach, J. Control. Release. 243 (2016) 109–120. 1681 
doi:10.1016/j.jconrel.2016.10.002. 1682 
[130] P. Calvo, C. Remuñán-López, J.L. Vila-Jato, M.J. Alonso, Development of positively charged 1683 
colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions, 1684 
Colloid Polym. Sci. 275 (1997) 46–53. doi:10.1007/s003960050050. 1685 
[131] P. Calvo, J.L. Vila-Jato, M.J. Alonso, Evaluation of cationic polymer-coated nanocapsules as 1686 
ocular drug carriers, Int. J. Pharm. 153 (1997) 41–50. doi:10.1016/S0378-5173(97)00083-5. 1687 
[132] C. Damgé, J. Vonderscher, P. Marbach, M. Pinget, Poly(alkyl cyanoacrylate) nanocapsules as 1688 
a delivery system in the rat for octreotide, a long-acting somatostatin analogue, J. Pharm. 1689 
Pharmacol. 49 (1997) 949–954. doi:10.1111/j.2042-7158.1997.tb06022.x. 1690 
[133] C. Vauthier, K. Bouchemal, Methods for the preparation and manufacture of polymeric 1691 
nanoparticles, Pharm. Res. 26 (2009) 1025–1058. doi:10.1007/s11095-008-9800-3. 1692 
[134] P. Couvreur, G. Barratt, E. Fattal, P. Legrand, C. Vauthier, Nanocapsule technology: a 1693 
review, Crit. Rev. Ther. Drug Carr. Syst. 19 (2002) 99–134. 1694 
doi:10.1615/CritRevTherDrugCarrierSyst.v19.i2.10. 1695 
[135] J.L. Grangier, M. Puygrenier, J.C. Gautier, P. Couvreur, Nanoparticles as carriers for growth 1696 
hormone releasing factors, J. Control. Release. 15 (1991) 3–13. doi:10.1016/0168-1697 
3659(91)90098-X. 1698 
[136] M. Gallardo, G. Couarraze, B. Denizot, L. Treupel, P. Couvreur, F. Puisieux, Study of the 1699 
mechanisms of formation of nanoparticles and nanocapsules of polyisobutyl-2-1700 
cyanoacrylate, Int. J. Pharm. 100 (1993) 55–64. doi:10.1016/0378-5173(93)90075-Q. 1701 
[137] S. Watnasirichaikul, T. Rades, I.G. Tucker, N.M. Davies, Effects of formulation variables on 1702 
characteristics of poly(ethylcyanoacrylate) nanocapsules prepared from w/o 1703 
microemulsions, Int. J. Pharm. 235 (2002) 237–246. doi:10.1016/S0378-5173(02)00002-9. 1704 
[138] S. Watnasirichaikul, T. Rades, I.G. Tucker, N.M. Davies, In-vitro release and oral bioactivity 1705 
of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion, J. 1706 















[139] S. Li, Y. He, C. Li, X. Liu, In vitro release of protein from poly(butylcyanoacrylate) 1708 
nanocapsules with an aqueous core, Colloid Polym. Sci. 283 (2005) 480–485. 1709 
doi:10.1007/s00396-004-1173-5. 1710 
[140] S. Watnasirichaikul, N.M. Davies, T. Rades, I.G. Tucker, Preparation of biodegradable insulin 1711 
nanocapsules from biocompatible microemulsions, Pharm. Res. 17 (2000) 684–689. 1712 
doi:10.1023/A:1007574030674. 1713 
[141] J.P. Devissaguet, H. Fessi, F. Puisieux, Process for the preparation of dispersible colloidal 1714 
systems of a substance in the form of nanocapsules, 5049322, 1991. 1715 
[142] H. Fessi, F. Puisieux, J.P. Devissaguet, N. Ammoury, S. Benita, Nanocapsule formation by 1716 
interfacial polymer deposition following solvent displacement, Int. J. Pharm. 55 (1989) R1–1717 
R4. doi:10.1016/0378-5173(89)90281-0. 1718 
[143] C. Prego, M. Fabre, D. Torres, M.J. Alonso, Efficacy and mechanism of action of chitosan 1719 
nanocapsules for oral peptide delivery, Pharm. Res. 23 (2006) 549–556. 1720 
doi:10.1007/s11095-006-9570-8. 1721 
[144] C. Prego, D. Torres, E. Fernandez-Megia, R. Novoa-Carballal, E. Quiñoá, M.J. Alonso, 1722 
Chitosan-PEG nanocapsules as new carriers for oral peptide delivery: effect of chitosan 1723 
pegylation degree, J. Control. Release. 111 (2006) 299–308. 1724 
doi:10.1016/j.jconrel.2005.12.015. 1725 
[145] A. Cadete Pires, Hyaluronic acid nanocapsules for the intracellular delivery of anticancer 1726 
drugs, University of Santiago de Compostela, University of Angers, 2016. 1727 
[146] P. Jakubiak, L.N. Thwala, A. Cadete-Pires, V. Préat, M.J. Alonso, A. Beloqui, N. Csaba, 1728 
Solvent-free protamine nanocapsules as carriers for mucosal delivery of therapeutics, Eur. 1729 
Polym. J. In Press (2017). doi:10.1016/j.eurpolymj.2017.03.049. 1730 
[147] A.H. Saberi, B. Zeeb, J. Weiss, D.J. McClements, Tuneable stability of nanoemulsions 1731 
fabricated using spontaneous emulsification by biopolymer electrostatic deposition, J. 1732 
Colloid Interface Sci. 455 (2015) 172–178. doi:10.1016/j.jcis.2015.05.037. 1733 
[148] F. Cournarie, M. Chéron, M. Besnard, C. Vauthier, Evidence for restrictive parameters in 1734 
formulation of insulin-loaded nanocapsules, Eur. J. Pharm. Biopharm. 57 (2004) 171–179. 1735 
doi:10.1016/S0939-6411(03)00191-7. 1736 
[149] C. Prego, D. Torres, M.J. Alonso, Chitosan nanocapsules as carriers for oral peptide delivery: 1737 
effect of chitosan molecular weight and type of salt on the in vitro behaviour and in vivo 1738 
effectiveness, J. Nanosci. Nanotechnol. 6 (2006) 2921–2928. doi:10.1166/jnn.2006.429. 1739 
[150] K. Krauel, N.M. Davies, S. Hook, T. Rades, Using different structure types of microemulsions 1740 
for the preparation of poly(alkylcyanoacrylate) nanoparticles by interfacial polymerization, 1741 
J. Control. Release. 106 (2005) 76–87. doi:10.1016/j.jconrel.2005.04.013. 1742 
[151] S. Vicente, B. Diaz-Freitas, M. Peleteiro, A. Sanchez, D.W. Pascual, A. Gonzalez-Fernandez, 1743 
M.J. Alonso, A polymer/oil based nanovaccine as a single-dose immunization approach, 1744 
PLoS One. 8 (2013) e62500. doi:10.1371/journal.pone.0062500. 1745 
[152] S. Vicente, M. Peleteiro, J.V. González-Aramundiz, B. Díaz-Freitas, S. Martínez-Pulgarín, J.I. 1746 
Neissa, J.M. Escribano, A. Sanchez, Á. González-Fernández, M.J. Alonso, Highly versatile 1747 
immunostimulating nanocapsules for specific immune potentiation, Nanomedicine 1748 
(London). 9 (2014) 2273–2289. doi:10.2217/nnm.14.10. 1749 
[153] S. Vicente, M. Peleteiro, B. Díaz-Freitas, A. Sanchez, Á. González-Fernández, M.J. Alonso, 1750 
Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a 1751 
needle-free vaccination strategy, J. Control. Release. 172 (2013) 773–781. 1752 
doi:10.1016/j.jconrel.2013.09.012. 1753 
[154] M. Aboubakar, F. Puisieux, P. Couvreur, M. Deyme, C. Vauthier, Study of the mechanism of 1754 















polymerization, J. Biomed. Mater. Res. 47 (1999) 568–576. doi:10.1002/(SICI)1097-1756 
4636(19991215)47:4<568::AID-JBM14>3.0.CO;2-X. 1757 
[155] G. Lollo, A. Gonzalez-Paredes, M. Garcia-Fuentes, P. Calvo, D. Torres, M.J. Alonso, 1758 
Polyarginine nanocapsules as a potential oral peptide delivery carrier, J. Pharm. Sci. 106 1759 
(2017) 611–618. doi:10.1016/j.xphs.2016.09.029. 1760 
[156] A. Graf, T. Rades, S.M. Hook, Oral insulin delivery using nanoparticles based on 1761 
microemulsions with different structure-types: optimisation and in vivo evaluation, Eur. J. 1762 
Pharm. Sci. 37 (2009) 53–61. doi:10.1016/j.ejps.2008.12.017. 1763 
[157] C. Prego, P. Paolicelli, B. Díaz, S. Vicente, A. Sánchez, Á. González-Fernández, M.J. Alonso, 1764 
Chitosan-based nanoparticles for improving immunization against hepatitis B infection, 1765 
Vaccine. 28 (2010) 2607–2614. doi:10.1016/j.vaccine.2010.01.011. 1766 
[158] C. Michel, M. Aprahamian, L. Defontaine, P. Couvreur, C. Damgé, The effect of site of 1767 
administration in the gastrointestinal tract on the absorption of insulin from nanocapsules 1768 
in diabetic rats, J. Pharm. Pharmacol. 43 (1991) 1–5. doi:10.1111/j.2042-1769 
7158.1991.tb05437.x. 1770 
[159] C. Damge, C. Michel, M. Aprahamian, P. Couvreur, J.P. Devissaguet, Nanocapsules as 1771 
carriers for oral peptide delivery, J. Control. Release. 13 (1990) 233–239. doi:10.1016/0168-1772 
3659(90)90013-J. 1773 
[160] M. Aboubakar, F. Puisieux, P. Couvreur, C. Vauthier, Physico-chemical characterization of 1774 
insulin-loaded poly (isobutylcyanoacrylate) nanocapsules obtained by interfacial 1775 
polymerization, Int. J. Pharm. 183 (1999) 63–66. doi:10.1016/S0378-5173(99)00045-9. 1776 
[161] M. Aboubakar, P. Couvreur, H. Pinto-Alphandary, B. Gouritin, B. Lacour, R. Farinotti, F. 1777 
Puisieux, C. Vauthier, Insulin-loaded nanocapsules for oral administration: in vitro and in 1778 
vivo investigation, Drug Dev. Res. 49 (2000) 109–117. doi:10.1002/(SICI)1098-1779 
2299(200002)49:2<109::AID-DDR4>3.0.CO;2-#. 1780 
[162] F. Cournarie, D. Auchere, D. Chevenne, B. Lacour, M. Seiller, C. Vauthier, Absorption and 1781 
efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic 1782 
rats, Int. J. Pharm. 242 (2002) 325–328. doi:10.1016/S0378-5173(02)00175-8. 1783 
[163] H. Pinto-Alphandary, M. Aboubakar, D. Jaillard, P. Couvreur, C. Vauthier, Visualization of 1784 
insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats, 1785 
Pharm. Res. 20 (2003) 1071–1084. doi:10.1023/A:1024470508758. 1786 
[164] P.J. Lowe, C.S. Temple, Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: 1787 
Protection Against Proteases and Effect on Intestinal Absorption in Rats, J. Pharm. 1788 
Pharmacol. 46 (1994) 547–552. doi:10.1111/j.2042-7158.1994.tb03854.x. 1789 
[165] A. Graf, K.S. Jack, A.K. Whittaker, S.M. Hook, T. Rades, Protein delivery using nanoparticles 1790 
based on microemulsions with different structure-types, Eur. J. Pharm. Sci. 33 (2008) 434–1791 
444. doi:10.1016/j.ejps.2008.01.013. 1792 
[166] N. Anton, P. Saulnier, C. Gaillard, E. Porcher, S. Vrignaud, J.P. Benoit, Aqueous-core lipid 1793 
nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules, Langmuir. 1794 
25 (2009) 11413–11419. doi:10.1021/la901565q. 1795 
[167] A.P. Kafka, B.J. McLeod, T. Rades, A. McDowell, Release and bioactivity of PACA 1796 
nanoparticles containing D-Lys6-GnRH for brushtail possum fertility control, J. Control. 1797 
Release. 149 (2011) 307–313. doi:10.1016/j.jconrel.2010.10.029. 1798 
[168] A.P. Kafka, T. Kleffmann, T. Rades, A. Mcdowell, Histidine residues in the peptide D-Lys6-1799 
GnRH: potential for copolymerization in polymeric nanoparticles, Mol. Pharm. 6 (2009) 1800 
1483–1491. doi:10.1021/mp900043e. 1801 
[169] K. Jelonek, J. Kasperczyk, Polyesters and polyester carbonates for controlled drug delivery, 1802 















[170] M. Tobío, R. Gref, A. Sanchez, R. Langer, M.J. Alonso, Stealth PLA-PEG nanoparticles as 1804 
protein carriers for nasal administration, Pharm. Res. 15 (1998) 270–275. 1805 
doi:10.1023/A:1011922819926. 1806 
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